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ABSTRACT
MECHANISM OF GABAB RECEPTOR-ACTIVATED INCREASES
IN L-TYPE CALCIUM CURRENT IN THE NEONATAL
MAMMALIAN HIPPOCAMPUS

Andrew Karls, B.S.
Marquette University, 2014
Activation of the metabotropic GABAB receptor has most commonly been
demonstrated to produce inhibitory effects on neurons, including the attenuation of
voltage-dependent calcium current. However, during the early neonatal period in
mammalian development, activation of GABAB receptors leads to an enhancement of
calcium current through a specific class of calcium channels, termed L-type channels,
(because they conduct Long-lasting current) . This response peaks at 7 days postnatal, and
is only demonstrated in a subset of cells. In the work presented here, the signal transduction
pathway of GABAB receptor-mediated increase of L-type current is described.
GABAB receptors couple to G proteins, traditionally believed to be Gαi/o. However,
previous data from the laboratory suggested that the enhancing effect observed was not due
to Gαi/o, but a different G protein not previously described in GABAB receptor signaling.
Indeed, when the Gαq G protein was knocked down in cell culture, the enhancement of Ltype channels was no longer observed. These data suggest that GABAB receptors couple
to Gαq G proteins to mediate calcium current enhancement.
Protein kinase C (PKC) had previously been demonstrated as a requisite member
of this pathway. Furthermore, there was precedence for PKC to work through
calcium/calmodulin-dependent kinase II (CaMKII) to enhance L-type current. However,
the isozyme of PKC was not known, nor was the involvement of CaMKII on L-type current
enhancement. Confocal imaging analysis suggests PKCα is the isozyme that is activated
by GABAB receptor activation, and pharmacological studies indicate CaMKII is not a
participant in this pathway.
In seeking to inhibit CaMKII signaling, highly specific pharmacological inhibitors
are often required. However, several inhibitors that were thought to be specific initially
demonstrate nonspecific effects. A newly synthesized molecule, CK59, has been described
to potently inhibit CaMKII activity (IC50 < 10 µm). However, data presented here describe
off-target effects of CK59, specifically its ability to inhibit voltage-gated calcium channels.
Treatment of cells with CK59 significantly reduced calcium influx in depolarized neurons,
whereas other CaMKII inhibitors did not change calcium influx. Thus, CK59 is not a
useful tool when studying the interplay between voltage-caged calcium channels and
CaMKII signaling.
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CHAPTER 1

INTRODUCTION
A cell’s ability to receive and integrate external stimuli is critical to maintain
processes required for its function. For example, stimulation of cells lining the gut cause
secretion of enzymes required to break down food and obtain nutrients. In a similar way,
the response to extracellular signals in neurons is critical to sensory perception, synaptic
plasticity, gene expression, and cellular communication via neurotransmission. One of
the most common ways neurons respond to extracellular stimuli is modulation of
intracellular calcium. Calcium serves as an effective signal, because it is kept very low
(low nM) within the neuron, but is much higher outside the cell (mM range). When
calcium is allowed to enter the cell through various channels or transporters, it stimulates
an intracellular change crucial to neuronal function or survival. Thus, the ability to
modulate calcium entry helps to influence myriad intracellular signals.
One of the most common ways to affect calcium entry is to change the behavior
of ion channels. This can be done directly, where a change in voltage or binding of a
ligand directly opens a channel. Also common are intracellular signaling pathways,
which cause calcium channels to be modified by various signaling molecules, such as
protein kinases. These pathways involve a signaling cascade, where binding of a
neurotransmitter to its receptor sets in motion a cascade of events. One example of this
cascade affecting calcium entry is the binding of the neurotransmitter γ-aminobutyric
acid (GABA) to the metabotropic GABAB receptor.
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A central focus of the Mynlieff laboratory is to understand how binding of GABA
to its receptor leads to an increase in the amount of calcium entering the cell. Several
studies have detailed the opposite effect: that GABAB receptor activation attenuates
calcium entry (Takahashi et al., 1998; Carter and Mynlieff 2004; Perez-Garci et al.,
2013). However, the Mynlieff lab showed that in hippocampal cell cultures derived from
rats early in development, GABAB receptor activation increases long lasting (L-type)
calcium current in a subset of cells (Carter and Mynlieff 2004; Bray and Mynlieff 2009;
Bray and Mynlieff, 2011). Furthermore, this response peaks between postnatal day 6
(P6) and P8 (Bray and Mynlieff, 2009). The phenomenon of GABAB receptor activation
leading to enhanced calcium entry had been identified only once before, in nonmammalian cells of the salamander retina (Shen and Slaughter 1999). Currently, there
are still very few reports of GABAB receptor-mediated enhancement of L-type current
(Park et al., 2010; Im and Rhim 2012), and no complete pathway or mechanism has yet
been described. Therefore, the enhancing effect of GABAB receptor activation on
enhanced L-type current continues to be an area of intense interest in the laboratory.
Tight regulation of intracellular concentrations is required for proper neuronal
growth and development (for review, see Michaelsen and Lohmann 2010). L-type
channels are the first calcium channels to be expressed in neurons; calcium flowing
through these channels is responsible for the initiation of regulatory events that may play
a role in neuronal differentiation (Pravettoni et al., 2000). Furthermore, the rats used in
experiments to be detailed here range in age from P6 to P8, roughly equivalent to a 6
month old human infant (Sengupta 2013). This time span is commonly associated with
seizure activity generated in the hippocampus (Korff and Nordli, Jr. 2006). How
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regulation of calcium flowing through L-type channels may be involved is unclear, but
there is emerging corollary evidence that L-type channels may play a role. First,
inhibiting L-type channels changes the distribution in chloride transporters necessary for
establishing a proper chloride ion gradient (Bray and Mynlieff 2009). Changes in
expression patterns of the same specific chloride transporters examined by Bray and
Mynlieff led to epilepsy-associated malformations of cortical development (Aronica et
al., 2007). Thus, one hypothesis is that during the rodent neonatal period (roughly
correlating to the first six months of human life), L-type channel activity is responsible
for changes that establish a neuron’s identity, including electrical properties. When Ltype current signaling is disrupted during development, the intrinsic electrical gradients
cannot be established. Thus, the circuit becomes vulnerable to epileptiform activity,
where neurons fire excessively in a synchronous manner. It can be hypothesized that any
pathway which functions to regulate intracellular calcium levels, such as GABAB
receptor activation in these cells, is imperative to proper function.
The principal focus of my research has been to further describe the components of
the signal transduction pathway, beginning with GABAB receptor activation, and
resulting in L-type current enhancement. Using work done by previous members of the
laboratory as a basis for my studies, I explored what signaling molecules might be
participating in this pathway; my results presented here suggest a novel mechanism that
corresponds with the Mynlieff laboratory’s discovery of a novel signaling pathway. A
recent report suggests the interplay between GABAB receptors and their regulation of
intracellular calcium may play a role in Parkinson’s disease, underscoring the importance
of understanding these data (Hillman et al., 2012). Furthermore, a better understanding of
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how cells communicate in general provides a better framework for potentially modifying
the system in certain diseases.

The Hippocampus
Studies in the Mynlieff laboratory examine dissociated neurons from the murine
hippocampus. The hippocampus is part of the medial temporal lobe of the brain, where it
plays a central role in formation and retrieval of memories. It is also a well-known site
for seizure formation. Morphologically, the hippocampus is composed of a “c”-shaped
sheet of neurons (the dentate gyrus) folded around another “c”-shaped sheet, known as
Ammon’s horn (Figure 1.2). This area can be subdivided into 3 distinct regions, CA1 –
CA3 (CA is rooted in the Latin term for Ammon’s horn). The neurons of the pyramidal
cell layer are densely packed through the CA1- CA3 region; however once it folds under
the dentate gyrus, neurons are much less dense. Thus, neurons with their cell bodies
outside the two cell layers tend to be much more diffuse; in general these cells are
identified as inhibitory GABAergic interneurons. The hippocampus is also described
depthwise with different strata (Figure 1.2). The stratum oriens is the most superficial
layer of the hippocampus, and sits above the primarily excitatory glutamatergic cell
bodies of the stratum pyramidale. Below the stratum pyramidale sits the stratum
radiatum, which is enriched in dendrites. Many of the Schaffer collateral fibers are found
here, as well as a diverse group of interneurons, rich in dendrites. Below the radiatum is
the stratum lacunosum and stratum moleculare, which are often grouped together, as well
as a host of interneurons. Finally, the dentate gyrus sits most ventral. Studies described
here focus primarily on neurons dorsal to the dentate gyrus, primarily in CA1 and CA3
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regions; for a more complete description of dentate gyrus structure and function, see
Scharfman, 2007.

Figure 1.1: Pathways through the
rodent hippocampus. Input enters
via the entorhinal cortex and
synapses on the granule cells of the
dentate gyrus (DG). DG axons
project to the CA3 region via mossy
fibers. CA3 pyramidal neurons
project to the CA1 region. Output is
primarily through the CA1
pyramidal neurons back to the
entorhinal cortex. (Figure courtesy
of neurosciencenews.com)

The hippocampus is perhaps the most intensely studied brain region; as such,
network connections and various cell types have been characterized in some detail. Input
entering the hippocampus flows unidirectionally via three well-defined pathways
(Andersen et al., 1973). First, the entorhinal cortex contains axons that project onto the
granule cells of the dentate gyrus; this is known as the perforant path. Second, neurons of
the dentate gyrus project their axons (known as mossy fibers and thus the mossy fiber
pathway) onto the pyramidal neurons of the CA3 region. Third, the CA3 region
pyramidal neurons contain branching axons that travel out of the hippocampus through
the fornix, as well as axons that synapse on CA1 pyramidal neurons within the CA1
region. Hippocampal output consists primarily of CA1 axons projecting back into the
entorhinal cortex. The CA1 region receives mostly excitatory glutamatergic input from
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the CA3 region; this input is extensively regulated by a network of GABAergic
interneurons. These interneurons serve to govern firing rate and ensure it occurs in
synchrony. There are at least 16 types of distinct interneurons in the hippocampus;
twelve synapse onto dendrites of pyramidal cells and four synapse onto other parts of
pyramidal neurons or onto other interneurons (Somogyi and Klausberger 2005;
Klausberger and Somogyi 2008; Klausberger 2009). Nearly all (92%) GABAergic
interneurons in the CA1 region synapse on pyramidal neuron dendrites (Megias et al.,
2001); however, little research has been conducted on the synapses on the cell bodies and
axons of these pyramidal neurons. The hippocampus, particularly the superior region
(mostly CA1 some CA3), contains a relatively high population of GABAergic
interneurons. While my hippocampal cell cultures contain a heterogeneous mixture of
pyramidal neurons and several type of interneurons, these cultures exclude the dentate
gyrus. They contain neurons only from the CA1 and CA3 regions, to decrease the
heterogeneity of the population (see methods). Furthermore, while hippocampal

Figure 1.2: Cross sectional slice of a P7
rat hippocampus.
Hippocamus was
frozen, sliced into 20 μM sections, and
stained with DAPI to visualize nuclei.
The stratum oriens (SO) is most
superficial, with the densely packed
stratum pyramidale (SP) sitting below.
The stratum radiatum (SR) contains
interneurons that project to CA. The
stratum moleculare/lacunosum (SLM)
sits on top of the dentate gyrus (DG),
which is densely packed with excitatory
dentate granule cells. Scale bar = 100
µM.
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interneurons are divided based primarily on antibody staining and morphology, the
physiological role for many of these interneurons remains elusive. Data presented here
present an opportunity to begin to define the physiological relevance of some of these
interneuron types, especially during development when maturation of circuitry is
occurring.

GABAB receptors
The GABAB receptors that we have demonstrated to enhance calcium current are
are G protein coupled receptors that are members of the class C7 transmembranespanning G protein coupled receptor family. The class C family also includes
metabotropic glutamate receptors, and its members share amino acid sequence identity of
approximately 30% (Katritch et al., 2013). Importantly, several important sites such as
the ligand binding domain, have much higher sequence identities, which allows for the
development of several structural homology models. (Katritch et al., 2013). Thus, much
of what is known about the various activation states and molecular interactions of the
GABAB receptor is based on models of the metabotropic glutamate receptor. However,
investigators have recently solved the extracellular domain of the receptor, both unbound
(Geng et al., 2012), and when it is bound to a ligand (Geng et al., 2013). Cystallography
data, homology modeling, and cloning work done in the early 1990’s have provided a
foundation of knowledge about GABAB receptor structure. It is composed of two distinct
gene products which encode the GABAB1 and GABAB2 subunits, respectively.
Physiological characterization showed that a functional receptor requires dimerization of
GABAB1 and GABAB2 subunits (Kaupmann et al., 1998; Jones et al., 1998; Kuner et al.,

8

1999); the GABAB1 subunit contains a motif that causes retention at the endoplasmic
reticulum (Margeta-Mitrovic et al., 2000). When GABAB1 and GABAB2 dimerize via a
coiled coil interaction on their C termini, the retention signal is hidden, and the receptor
will be trafficked to the membrane (Calver et al., 2001; Margeta-Mitrovic et al., 2001).

Figure 1.3: Schematic structure of GABAB receptors. (a) The ligand binds to the
GABAB1 subunit, and the G protein couples to the GABAB2 subunit. GABAB1a is shown
with sushi repeats. (b) Effects of GABAB receptor activation on inwardly rectifying
potassium currents shown in the presence and absence of auxiliary subunits. KCTD,
potassium channel tetramerization domain. Adapted by permission from Macmillan
Publishers Ltd: [Nature Reviews Neuroscience] (13, 380-394), copyright (2012).

The simplest view of GABAB receptor signaling is that the B1 subunit binds the
ligand, whereas B2 couples to the G protein (Figure 1.3a). Homology models have
suggested the presence of a “venus flytrap” model, where the binding site is between two
lobes on the B1 N-terminus (Galvez et al., 1999). The first step in signal transduction is
the closure of the lobes around the ligand (Galvez et al., 2000). Interestingly, chimeric
models where the B2 N-terminus is replaced with the B1 N-terminus decreases ligand
affinity (Galvez et al., 2001; Geng et al., 2012). Therefore, while B1 is the site of
binding, there appears to be intramolecular communication and possible interaction of B2
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to promote the most efficient ligand binding. Just as chimeric studies were used to show
the importance of the B2 N-terminus in ligand binding, they were also used to describe in
detail the components for G protein coupling. When B2 was swapped with any of the B1
intracellular loops, the result was formation of a nonfunctional receptor (MargetaMitrovic et al., 2001). Furthermore, specific point mutations within either intracellular
loop 2 or 3 can also render the receptor nonfunctional (Havlickova et al., 2002; Duthey et
al., 2002). The generation of GABAB subunit knockout mice has generally supported
chimeric studies. GABAB1 knockouts do not display electrophysiological or biochemical
activity when a ligand is present (Prosser et al., 2001; Schuler et al., 2001; Queva et al.,
2003). However, responses of GABAB2 knockouts can be measured
electrophysiologically in the hippocampus (Gassmann et al., 2004). This is suggestive
that GABAB1 subunits can function autonomously or, more likely, promiscuously with
other receptors. Recent evidence has shown GABAB2 functional interaction with M2
muscarinic receptors, expanding the possibilities beyond simple GABAB1/GABAB2
heteromers (Boyer et al., 2009).When GABA receptors were cloned, it was expected that
there would be a host of splice variants and isoforms to correlate with the diverse
signaling attributed to the receptor (Padgett and Slesinger 2010). Instead, only two splice
variants of GABAB1 were discovered, GABAB1a and GABAB1b (Kaupmann et al., 1997).
GABAB1a and GABAB1b show no physiological or pharmacological distinction when
expressed in heterologous expression systems (Brauner-Osborne and Krogsgaard-Larsen
1999; Ulrich et al., 2007). However, only GABAB1a contains 2 “sushi” domains,
believed necessary for axonal targeting. This suggests B1a is primarily axonal, whereas
B1b is dendritic. Knockout studies have verified these localizations (Vigot et al., 2006).
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GABAB receptor signaling has traditionally been described by its coupling to a
pertussis toxin-sensitive Gαi/o G protein (Pinard et al., 2010). Ligand binding causes the
G protein (both Gα and Gβγ) to release from the receptor in a GTP-dependent fashion.
Downstream targets of the G protein itself often initiate a second messenger cascade
which can have a wide range of effects on physiological functions (Figure 1.3). G

Figure 1.4: Downstream effectors of GABAB receptors. (a) Presynaptically, GABAB receptors
decrease both evoked and spontaneous neurotransmitter release. (b) Postsynaptically, GABAB
receptor activation results in increased outward potassium current, decreased activity of PKA,
and reduced calcium currents. Reprinted by permission from Macmillan Publishers Ltd:
[Nature Reviews Neuroscience] (13, 380-394), copyright (2012).
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proteins also commonly target ion channels as a way of regulating excitability. The three
most well understood targets of Gαi/o G proteins linked to GABAB receptors are voltagegated calcium channels, inwardly rectifying potassium channels, and the enzyme
adenylate cyclase (Gassmann and Bettler 2012).
Adenylyl cyclase is the enzyme that converts ATP into cyclic AMP (cAMP), one
of the most ubiquitous second messengers in neurons. In this case it is the Gαi/o activated
by GABAB receptors that inhibits activity of this enzyme (Nishikawa et al., 1997). By
doing so, cAMP levels are reduced, thus resulting in reduction of downstream kinase
activation, specifically protein kinase A (Figure 1.4b). Of particular interest is that under
certain conditions, GABAB receptors can actually increase cAMP levels. While the Gαi/o
is inactivated by regulator of G protein signaling (RGS) proteins, the βγ subunits inhibit
the GTPase activity of Gαs during β-adrenergic receptor stimulation. This leads to
increased affinity of Gαs for adenylate cyclase. Thus, GABAB receptor activation can
indirectly assist in the increase of adenylyl cyclase activity, resulting in increased protein
kinase A activity (PKA, Robichon et al., 2004). This is important to work presented here,
which also examines the ability of GABAB receptors to produce a bidirectional response
via a different mechanism affecting voltage-gated calcium channel (VGCC) function.
G-protein inwardly rectifying potassium channels (GIRK channels) open to
produce a slow inhibitory postsynaptic potential (Figure 1.4b). This occurs because
positive potassium ions flow out of the cell, reducing its excitability. These GIRK
channels hyperpolarize the membrane potential, and are the primary effectors of GABAB
receptors postsynaptically (Misgeld et al., 1995). In contrast to the inhibitory effects in
P/Q- and N- channels, the currents across GIRK channels are enhanced by the βγ subunit
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directly (Reuveny et al., 1994; Wickman et al., 1994). GIRK channels are homo- or
heterotetramers; it is thought that the subunit composition of the GIRK channel accounts
for its differing interactions with the Gβγ, and thus accounts for the large differences in
GIRK channel kinetics in response to GABAB receptor activation (Cruz et al., 2004;
Padgett and Slesinger 2010). This hypothesis appears to be partially correct, although the
recently discovered GABAB auxiliary subunits also appear to play an important role in
influencing GIRK channel kinetics (Gassmann and Bettler 2012).
For many years there have been discrepancies about the differing kinetics seen
when GABAB receptors regulate GIRK channels in native neurons versus those in
expression systems. For example, activation kinetics were always much faster in native
neurons; this difference was thought to be due to the subunit composition of the GIRK
channel (Gassmann and Bettler 2012). However, biochemical evidence has shown that
GABAB receptors can assemble with auxiliary potassium channel tetramerization domain
(KCTD) proteins (Schwenk et al., 2010). These four proteins form a homotetramer that
can bind to the GABAB2 C-terminus (Figure 1.3b). Expression of these KTCD tetramers
with GABAB receptors in heterologous expression systems abolished the differences seen
in these model systems when KCTD proteins were not included (Schwenk et al., 2010).
Thus, it appears that the GABAB receptor auxiliary subunits may significantly change the
function of the receptor. As pointed out by the authors who made the discovery
originally, KCTD proteins could influence any part of the signaling complex, including
what the downstream effector or channel of the GABAB receptor may be (Schwenk et al.,
2010).
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GABAB receptors have been shown to couple to all types of high voltage
activated calcium channels (P-, Q-, N-, and L-), with the exception of the R channel
(Mintz and Bean 1993; Guyon and Leresche 1995; Huston et al., 1995; Harayama et al.,
1998; Li and Stern 2004; Vigot et al., 2006). Dogmatically, ligand binding to the
GABAB receptor liberates the βγ subunit to directly bind to the presynaptic VGCCs.
This slows the activation of the VGCC and decreases its activity 10-50% (Figure 1.4a,
Huston et al., 1990; Menon-Johansson et al., 1993; Guyon and Leresche 1995). Less
presynaptic calcium inhibits vesicular neurotransmitter release. To a lesser degree than
presynaptic inhibition, GABAB receptor signaling is also involved postsynaptically. For
example, in the supraoptic nucleus, release of βγ caused by GABAB receptor activation
leads to a decrease in firing because of the reduction in calcium currents (10-25%,
Harayama et al., 1998). Finally, activation of GABAB receptors has also been shown to
increase L-type calcium current (Shen and Slaughter 1999; Carter and Mynlieff 2004;
Bray and Mynlieff 2011; Park et al., 2010). While there are fewer descriptions of this
phenomenon, it is not pertussis toxin sensitive (Bray and Mynlieff 2011), and is likely
mediated by a Gαq G protein which initiates a signaling cascade. This document will
spend much time describing what is known about the pathway, and thus it will not be
detailed presently.

G Proteins
GABAB receptors are known as G protein coupled receptors (GPCRs) because they
associate in signaling complexes with molecules known as a guanine nucleotide-binding
proteins. Simply referred to as heteromeric G proteins, these complexes are composed of
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an α subunit, as well as β and γ subunits, which closely associate with each other. Upon
ligand binding to the GPCR on the extracellular side of the membrane, the G protein
associated with the GPCR on the intracellular side of the membrane will become
activated (Figure 1.5). The conformational change that takes place within the GPCR
allows the G protein to exchange bound GDP for GTP on its Gα subunit. This exchange
causes the Gα subunit to dissociate from the GPCR and the Gβγ subunit complex. Both
the Gα and Gβγ can serve to initiate signal transduction cascades. Termination of
signaling occurs when the intrinsic GTPase activity of the Gα hydrolyses GTP to GDP,
restoring the affinity of the Gα to Gβγ. Proteins known as GTPase activating proteins
(GAPs) increase the rate at which hydrolysis occurs; in certain cases, the molecule
targeted by the G protein may possess GAP activity and thus increase rate of deactivation
(G protein signaling reviewed in McCudden et al., 2005; Wettschureck and Offermanns
2005; Milligan and Kostenis 2006). Bacterial toxins have aided greatly in determining
the function and molecular mechanisms of various G protein families. Cholera toxin
(CTX) produces a constitutively active α subunit of Gαs (Moss and Vaughan 1979; Van
Dop et al., 1984); pertussis toxin (PTX) causes Gαi/o to remain permanently bound to
GDP (inactive) and uncouples the heterotrimeric complex of Gαi/o G proteins from their
GPCR (Katada and Ui 1982; Kurose et al., 1983).
G proteins are named based on the identity of their α subunit. They are grouped
into families, often exerting similar effects, and sharing significant sequence similarity.
There are currently four families of Gα proteins with a total of 14 members (Simon et al.,
1991). A broad description of the divisions and functions of various G proteins can be
found in table 1. Of particular interest to this project is the Gαq family. The Gαq family
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comprises 4 members: Gαq, Gα11, Gα14, and Gα15/16 (Mizuno and Itoh 2009). Gαq is
found in all tissue types, and its α subunit amino acid sequence is used for comparison of
sequence identity with other members (reviewed in Mizuno and Itoh 2009). Gα11
demonstrates 90% sequence similarity with Gαq, and is also distributed across all tissue
types. Gα14 demonstrates 80% sequence similarity with Gαq, and is most commonly
found in non-neuronal tissues, such as the kidney, liver, and lung; finally, Gα15/16 is also
not distributed in nervous system, but rather in hematopoetic cells only. Its α subunit
demonstrates 57% sequence similarity to that of Gαq. Structurally, all four

G protein
family

Members

Gαs

αs,
αolf

Gαi/o

Distribution

Ubiquitous
Olfactory
Epithelium
αi1, αi2, αi3, Ubiquitous
αo,
Neuronal
αz,
Neuronl
αt-r,
Retinal rods
αt-c,
Retinal cones
αgust
Taste buds

Gαq

αq, α11
α14
α15/16

Gα12/13

α12, α13

Ubiquitous
Kidney, lung
Hematopoetic
cells
Ubiquitous

Pharmacological Common
Inhibitor
physiological
action
Cholera Toxin
Activates adenylyl
cyclase
Pertussis Toxin

Inhibits adenylyl
cyclase, activates
GIRK channels
inhibits N-type
channels
increases PDE 6
activity (for rods,
cones, and taste
buds)

YM-254890 (all
but α15/16)

Activate β isoforms
of phospholipase C

Activate small G
proteins including
RhoA

Table 1: Families of G proteins. Members are divided based on their α subunit, and described
by their pharmacology, most common tissue distribution, and general physiological role. Adapted
from Wettschureck and Offermanns 2005.
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isoforms are similar, composed of a helical domain with 5 α helices, a switch region
(with both α helices and β sheets), and a GTPase domain. The physiological role of the
Gαq family is to activate β isoforms of phospholipase C (PLCβ), which in turn catalyzes a
reaction in which phosphatidylinositol bisphosphate (PIP2) is cleaved into inositol
trisphosphate (IP3) and diacylglycerol (DAG). The result of cleaving PIP2 and generating
these second messengers is to release calcium from intracellular stores (via the IP3
receptor) and activate protein kinase C (PKC), both of which participate in a range of
cellular processes (signaling pathway reviewed in Rhee 2001). All four isoforms of
PLCβ (β1-β4) are stimulated by the Gαq family and their associated Gβγ, although
different Gαq isoforms preferably activate different PLCβ isoforms. For example, the
Gαq isoform is a poor activator of PLCβ-2, but not the other three isoforms of PLCβ
(Hepler et al., 1994; Jiang et al., 1994); Gα15/16 can activate only PLCβ 1-3 (Kozasa et al.,
1993). The mechanism by which the Gαq family members activate PLCβ is unknown;
however, truncation experiments have shown that the PLCβ C-terminus is required for
Gαq interaction (Park et al., 1993). On the Gαq protein, the third helix and linker to the
fourth β sheet change conformation when PLCβ is activated (Venkatakrishnan and Exton
1996). Truncation mutations verified these as essential regions. In terms of termination,
it was shown, somewhat surprisingly, that the intrinsic GTPase activity of Gαq was rather
low; however, in the presence of PLCβ-1, activity significantly increased. This result
indicated PLC β-1 acts as a GAP to stimulate hydrolysis of GTP bound to Gαq (Chidiac
and Ross 1999). While the first bacterial toxins such as PTX or CTX had no measurable
action on the activity of Gαq G proteins, recently two compounds have been isolated that
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Figure 1.5: Schematic structure
of G protein activation. Agonist
binding to the receptor causes
GDP to be exchanged for GTP,
the complex to dissociate from
the receptor, and the α and βγ
subunits to initiate a signaling
cascade.
Reprinted
by
permission from Macmillan
Publishers Ltd: [Nature] (420,
716-717), copyright (2002).

modulate Gαq signaling. The pathogenic bacterium P. multocida produces a protein
known as PMT, which acts as a mitogen; pharmacologically, this compound appears to
facilitate Gαq coupling to PLCβ-1 leading to the same response elicited by receptors
coupled to Gαq family members (Wilson and Ho 2004). Importantly, PMT does NOT
activate Gα11 mediated pathways, because the Gα11 isoform is missing a critical region in
its helical domain where PMT appears to induce activation. A second modulator, YM254890, has been isolated from Chromobacterium culture broth; it reduces the enhanced
calcium signals induced by Gαq, Gα11, and Gα14, but not Gα15 (Takasaki et al., 2004).
While the molecular mechanism is not yet known, YM-254890 is the most specific
inhibitor of Gαq signaling currently available.

Voltage-gated Calcium Channels
Calcium entry into neurons is a tightly regulated process. Various intracellular storage
sites, membrane transporters, and ion channels collectively determine the concentration
of calcium within the cell. One well studied mechanism for calcium entry is the opening
of voltage-gated calcium channels (VGCC) in response to depolarization. These
channels are heteromers, composed of an α1 pore-forming subunit, as well as auxiliary
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subunits which modify expression and kinetics of the channel. Two classes of VGCC
have been identified, based on whether they activate at low voltages (LVA, Va ~ -46 mV,
(Klockner et al., 1999) or high voltages (HVA, Va ~ +10 to -20 mV, Catterall et al.,
2005). VGCCs are subdivided based on sequence identity, pharmacology, and kinetics.
Collectively, there are a total of 10 α1 subunits classified into three families (reviewed in
Ertel et al., 2000, table 2). Within these families, there is greater than 70% sequence
identity, and less than 40% identity between families (Catterall 2011). LVA channels
(Cav 3.x) are known as T-type channels; they produce a transient current which helps
regulate excitability in neurons, aid in secretion in the kidney and liver, and regulate
smooth muscle contraction and proliferation (Cueni et al., 2009; Iftinca and Zamponi
2009). Cav 2.x channels are associated with neurotransmitter release in the central
nervous system and at the neuromuscular junction (Weiergraber et al., 2006; Snutch
2005; Nimmrich and Gross 2012). The Cav 1.x family contains isoforms 1.1 – 1.4. Cav
1.1 channels are found in the transverse tubules of skeletal muscle (Flucher and FranziniArmstrong 1996) where they are required for excitation contraction coupling (Rios et al.,
1992). Cav 1.4 channels are located in retinal photoreceptors and bipolar cells of the eye,
and are necessary for phototransduction (Baumann et al., 2004). Cav 1.2 channels are
found in cardiac and smooth muscle, and function in excitation-contraction coupling
(Striessnig 1999). Cav 1.3 channels are located on sensory cells, such as cochlear hair
cells, functioning to promote neurotransmitter release (Michna et al., 2003). Importantly,
Cav 1.2 and Cav 1.3 are also both found in neurons. In neurons, Cav 1.2 channels are
localized primarily postsynaptically on dendritic shafts and spines (Di Biase et al., 2011);
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Cav 1.3 channels are located preferentially on proximal dendrites and cell bodies (Hell et
al., 1993).

Channel
Voltage
α1 Subunit
Identification Activation identification
L-type
HVA
Cav 1.1 – 1.4

P/Q-type

HVA

Cav 2.1

N-type

HVA

Cav 2.2

R-type

HVA

Cav 2.3

T-type

LVA

Cav 3.1 – 3.3

Pharmacological Common tissue
antagonists
distribution
Dihydropyridines All muscle types,
neurons, retinal
cells
ω-Agatoxin IVA Neurons, heart,
pancreas
ω-Conotoxin
Neurons
GVIA
SNX-483
Neurons, heart,
testes
Ethosuximide
Brain, kidney,
placenta

Table 2: Divisions of voltage-gated calcium channels based on pharmacology, kinetics, and
sequence identity of the pore-forming α1 subunit. Adapted from Ertel et al., 2000.

The α1 subunit of Cav’s is a large protein (190-250 kDa) comprising four domains
(I-IV, Figure 1.6a). Each domain contains six membrane-spanning segments (S1-S6).
Within the transmembrane segments, S4 is the voltage sensor, and the loop between S5
and S6 serves as the selectivity filter and determines ionic conductance (Catterall 2011).
The intracellular loops serve as sites where protein-protein interactions occur. For
example, G proteins have been shown to regulate N-type channels between domains I and
II, the same loop where the auxiliary β subunit associates (De Waard et al., 1997; Herlitze
et al., 1997). Furthermore, the loop between domains II and III is the site of direct
interaction with SNARE proteins for Cav 2.x channels (Sheng et al., 1994; Rettig et al.,
1996). The heavily spliced C-terminal end of neuronal calcium channels contains an IQlike motif that can interact with calcium binding proteins such as calmodulin (Lee et al.,
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1999); perhaps most interestingly, L-type calcium channels ( can regulate transcription
when a spliced fragment binds to a nuclear protein (Gomez-Ospina et al., 2006). In
addition to the central pore-forming α1 subunit, VGCC complexes associate with several
auxiliary subunits (Figure 1.6b). The α2 and δ subunits are linked by disulfide bonds
(Gurnett et al., 1996) and, along with the intracellular β subunit, help regulate trafficking,
surface expression, α1 stability, and kinetics (Buraei and Yang 2013; Dolphin 2013).
Some types of calcium channels also associate with transmembrane γ auxiliary proteins
as well, and its effects are determined based on the isoform of beta subunit expressed
(Yang et al., 2011).

A.

B.

Figure 1.6: 2D and 3D
structure of voltage-gated
calcium channels.
(A)
Structure of the α1 subunit is
comprised of four domains,
each with 6 membranespanning helices. Interacting
molecules, such as PKC,
CaMKII, and the G protein βγ
subunit modulate channel
activity via association with
the intracellular N- and Ctermini, or intracellular loops.
Figure
adapted
with
permission from Cold Spring
Harbor Laboratory Press.
Catterall W.A., Cold Spring
Harb
Perspect
Biol
2011;3:a003947. (B) Calcium
channel
complex
with
auxiliary subunits embedded
in the membrane.
These
subunits influence trafficking,
surface
expression,
and
behavior of the channel itself.
Figure courtesy of Dr. Tuck
Wah Soong, Yong Loo Lin
School of Medicine, National
Singapore University.
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The focus of much of this work involves the increased calcium flowing through
neuronal L-type (Cav 1.2 and 1.3) LTCCs. These LTCCs can be distinguished from other
VGCCs by their sensitivity to dihydropyridines (Kanngiesser et al., 1988). However
there is not a pharmacological means to separate the 4 isoforms of LTCCs; a series of
knockout studies and experiments done in heterologous expression systems have
attempted to describe the differences in function. Global knockout of Cav 1.2 led to
embryonic lethality because of its importance in the heart (Seisenberger et al., 2000).
However, conditional knockouts of Cav 1.2 in the cerebral cortex and hippocampus
showed a loss of late phase long term potentiation and impairment of spatial memory
formation (Moosmang et al., 2005; White et al., 2008). These data were associated with
decreased cyclic AMP response element (CRE) dependent transcription in the CA1
region of the hippocampus, linking Cav 1.2 with impairment in memory formation. The
generation of Cav 1.3 knockout animals has suggested a specific function for this LTCC
subtype as well. Studies examining these animals revealed no obvious phenotypic defect
or problems with motor function (Platzer et al., 2000). Instead, Cav 1.3 mice are deaf,
corresponding to a role for L-type current in cochlear hair cells (Platzer et al., 2000). In
addition, conditional knockout of Cav 1.3 also showed diminished slow
afterhyperpolarization, an attribute often associated with increased learning and memory
(Gamelli et al., 2011).
Several biophysical differences described between Cav 1.2 and Cav 1.3 are based
primarily on work done in Xenopus oocytes. First, the activation threshold for Cav 1.3 is
substantially more negative (around -55 mV) than for Cav 1.2 (around -30 mV,
Lipscombe et al., 2004). This means that Cav 1.3 channels may activate at
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depolarizations that are below threshold for action potential generation, which could
indicate involvement in different signaling pathways. Second, dihydropyridines do not
antagonize channels equally (Xu and Lipscombe 2001). For example, the sensitivity to
LTCC antagonist nimodipine varies widely: IC50 for Cav 1.2 is 139 nM, whereas for Cav
1.3 it is 3 µM (Xu and Lipscombe 2001). Thus, early studies using a low micromolar
concentration may still have some LTCC contribution to overall current. Finally, Cav 1.2
channels open significantly faster than do Cav 1.3 channels (Xu and Lipscombe 2001).
Notably, these studies were done in heterologous expression systems, where auxiliary
subunits and potentially other interacting proteins were missing. Whether these
differences exist in native neurons is unknown.
Not only are there functional differences in the properties of Cav 1.2 and Cav 1.3,
but there are differences in expression patterns as well. 80% of LTCCs in the brain are
composed of the Cav 1.2 isoform compared to 20% Cav 1.3 (Hell et al., 1993). However,
during hippocampal development, the composition is changing. During the early
neonatal period, expression of Cav 1.2 was relatively high, but began to decrease by P12
(Kramer et al., 2012). This is in contrast to Cav 1.3, whose expression levels were low at
P0 but increased steadily into adulthood (Kramer et al., 2012). Thus, any developmental
phenomenon that correlates with a change in LTCC may involve the Cav 1.2 isoform,
because of its relatively higher abundance during development.

Protein kinase C
Protein kinase Cs (PKCs) are a family of serine/threonine protein kinases that serve as
secondary effectors in diverse pathways, from immune responses to regulation of
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transcription. Currently, there are 15 known isozymes of PKC, with divisions based on
requirements for activation (table 3, reviewed in Zeng et al., 2012; Wu-Zhang and
Newton 2013). Conventional isozymes require both DAG and calcium to be activated,
whereas novel isozymes require DAG but not calcium. Atypical PKCs require neither
calcium nor DAG for activation. Many PKC isozymes may exist within a single cell,
though their method of activation and localization may be different (Roisin and Barbin
1997). Therefore, it is possible for many PKCs to regulate the activity of a single cell,
depending on the subcellular localization of PKC. Structurally, PKCs are generally
comprised of regulatory domains (C1 and C2) and a catalytic domain (C3 and C4),
connected by a linking domain (Figure 1.7, PKC structure reviewed in Steinberg 2008).
There is also a pseudosubstrate that binds the catalytic domain. The C1 domain contains
the binding site for DAG as well as phorbol esters, which are structural analogs of DAG
that mimic its activity. Work presented here focuses on the actions of specific
conventional and novel isozymes of PKC because the effect of GABAB receptor
activation on calcium current is mimicked by phorbol ester activation (Bray and Mynlieff
2011). The C2 domain binds phosphatidylserine (PS) and calcium in conventional
isozymes, but sequence alignment shows the calcium binding segment of the protein is
absent in novel and atypical PKCs; thus there is no calcium required for activation of

PKC Family

Isoforms

Conventional

α,βI, βII, γ

Novel
Atypical

δI, δII, δIII, ε, η, θ
ι, ζ, λ,

Requirements for
activation
Calcium, DAG,
phospholipids
DAG, phospholipids
Phospholipids

Phorbol ester
sensitivity
Sensitive
Sensitive
Insensitive

Table 3: 3 Families of PKC isozymes are divided based on their requirements for activation.
Only the conventional and novel isoforms are sensitive to phorbol esters.
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these isozymes. To become catalytically active, the C1 domain must bind DAG;
anchoring proteins help position PKCs near the membrane. A phospholipid, most
commonly PS, also embedded in the membrane, binds to the C2 domain, which causes a
conformational change in the PKC such that the pseudosubstrate is removed. For
conventional isozymes, binding of calcium to the C2 domain increases its affinity for PS.
With the pseudosubstrate removed, other proteins such as receptor for activated C kinase
(RACK) help position PKCs close to their substrates (Schechtman and Mochly-Rosen
2001). The active site of the catalytic domain is a bilobal structure, which forms a cleft.
It is within this cleft that both ATP and the substrate bind. Importantly, a hallmark of
PKC activation is the necessity for translocation to the plasma membrane.
All PKC isozymes are expressed in the mammalian central nervous system.
However, their expression levels vary widely during development (Roisin and Barbin
1997). For example PKC γ is not expressed embryonically; only after P14 is any
expression detectable when it begins to rise rapidly. This is in contrast to an isoform
such as PKC ε, where expression is already high at the earliest time point examined, E17.
It continues to increase, though much more gradually than PKC γ. Expression also varies
depending on the tissue examined. In cardiac tissue, PKCα is expressed at a relatively

Figure
1.7:
Domain
classifications of the 3 PKC
families.
PS,
phosphotidylserine binding
domain; C1a, C1b, C2,
calcium binding domains;
C2L, calcium-like domain;
C3 and C4, catalytic domain.
Adapted by permission from
Macmillan Publishers Ltd:
[Journal of Investigative
Dematology] (129, 23302332), copyright (2012).
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high level in embryonic day 14 (E14) rats, with expression peaking in the neonate. As the
animal ages, PKCα expression decreases threefold by adulthood (Rybin and Steinberg
1994). In hippocampal tissue, PKCα is low at E17 and steadily increases into adulthood.
At P7, expression has reached approximately half its maximal expression and has
increased almost fivefold from embryonic levels (Roisin and Barbin 1997). These
expression data are pertinent for experiments attempting to determine the identity of a
particular isozyme at a given age.
PKCs have been shown to phosphorylate L-type channels on both the I-II and IIIII intracellular loops (Zamponi et al., 1997). How this phosphorylation modifies channel
behavior and L-type current is still not clear, as both an increase and a decrease in L-type
current have been reported. Differences in response vary with cell type as well as with
the isozyme of PKC that is activated. For example, when α-adrenergic receptors were
stimulated in cardiac myocytes, L-type current was enhanced in a PKC dependent
manner. Notably, this pathway also required the activity of calcium/calmodulin
dependent kinase II (CaMKII, O-Uchi et al., 2008). In heterologous systems, PKC
activation with phorbol esters reduced whole cell current of Cav 1.3 channels (Baroudi et
al., 2006). Furthermore, single channel recording of Cav 1.3 channels showed PKC
activation decreased mean open time, increased mean closed time, and thus led to a
reduction in open probability (Chahine et al., 2008). In some cases, L-type current is not
affected at all. In dorsal root ganglion neurons obtained from embryonic mice, PKC
activation did not change L-type current while decreasing N-type current (Gross and
MacDonald 1989). Most important to the work presented here, GABAB receptor
mediated calcium enhancement through L-type channels in neonatal hippocampal
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cultures requires PKC activity (Bray and Mynlieff 2011). When a host of inhibitors are
used, enhancement is abolished. Conversely, when phorbol esters are used to mimic
activation, the enhancing response is observed. Thus, it is difficult to make broad
statements about the functions of PKCs and L-type calcium channels because any change
in condition (source of cells, age of the animal, isozyme of PKC) seems to produce a
unique response.

Calcium/Calmodulin-dependent Protein Kinase II
CaMKII is found throughout the brain, where it makes up 1-2% of total protein.
Structurally, it has a unique arrangement; there are twelve functional domains attached to
a gear-shaped core (Fink and Meyer 2002). The twelve subunits are grouped into what
appears to be two stacked hexamers; each subunit contains a catalytic, autoregulatory,
and association domain (Figure 1.8). There are two primary subunits in neurons, α- and
βCaMKII. Isoforms have a high sequence identity, with the exception of a 30 amino acid
insertion in the β isoform. As a serine/threonine kinase, the catalytic domain binds both
ATP and substrate; however the autoregulatory domain contains a pseudosubstrate site
that binds to the catalytic domain, preventing catalytic activity. Perhaps the most
important residue of CaMKII is Thr 286 (or Thr 287 in βCaMKII). When this residue is
phosphorylated, the pseudosubstrate can no longer associate with CaMKII and
autoinhibition is removed, and thus the catalytic domain is active. In a stepwise process,
CaMKII will autophosphorylate and become active, even if calcium and calmodulin are
no longer present (for more detailed review on CaMKII activation, see Hudmon and
Schulman 2002b; Hudmon and Schulman 2002a). Studies have shown that L-type
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channels are substrates for CaMKII. Both the α1 subunit (Hudmon et al., 2005) and
specific beta isoforms of Cav 1.2 (Abiria and Colbran 2010) are shown to be
phosphorylated. In either case, the calcium currents are enhanced through calciumdependent facilitation, with sites of phosphorylation on the Cav 1.2 α1 subunit having
been identified (Blaich et al., 2010). Cav 1.3 channels are also phosphorylated by
CaMKII, but in a more indirect manner. CaMKII enhancement of Cav 1.3 currents
occurs only in the presence of the protein densin, which has a binding site on the Cterminal tail of Cav 1.3 (Jenkins et al., 2010). Neither CaMKII nor densin alone will
produce this current enhancement, but together, the two augment L-type current during
repetitive stimuli. Thus, both neuronal forms of L-type channels have CaM binding sites,
both are substrates for CaMKII, and both demonstrate current enhancement when
phosphorylated by CaMKII. Since PKC, a known component of the pathway by which
GABAB receptors lead to L-type current enhancement, has also been shown to
phosphorylate CaMKII, and since CaMKII can enhance L-type current, part of the work
described herein was to examine the potential role CaMKII may play in the enhancement
of L-type current by GABAB receptors.
The current research focuses on determining the G protein that mediates calcium
current enhancement, the isozyme of PKC that is involved in the pathway, and whether or
not CaMKII participates in L-type calcium current enhancement.
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Figure 1.8: Domain organization
and assembly of CaMKII. (a) A
single subunit of CaMKII includes,
a regulatory, catalytic, and
oligomerization domain. (b) Twelve
subunits assemble into a double
hexemer. The highly homologous
βCamKII subunit includes an Factin localization insert for
trafficking to the post-synaptic
density. Adapted from Current
Opinion in Neurobiology, 12(3).
Fink, C.C. and Meyer T., Molecular
mechanisms of CaMKII activation
in neuronal plasticity, pp. 293-299,
Copyright (2002), with permission
from Elsevier.
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CHAPTER 2

MATERIALS AND METHODS

Isolation of hippocampal neurons by cell culture
All animal protocols were approved by the Marquette University Institutional
Animal Care and Use Committee and followed guidelines provided by the United States
Public Health Service. Hippocampal neurons were isolated by a method that is specific
for postnatal rats and has been shown to keep neurons alive for up to three weeks in
culture (Mynlieff 1997). Sprague-Dawley rat pups aged 6-8 days postnatal were
anesthetized with CO2 and immediately sacrificed by decapitation. The head was placed
in 70% ethanol for 3 minutes for sterilization, then rinsed in sterile rodent Ringer’s
solution (146 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 11 mM
ᴅ-glucose, pH 7.4 with NaOH). Dissections were performed within a NuAire table top
horizontal airflow workstation (Plymouth, MN) using sterile technique. The hippocampi
were excised from the brain and placed into cold (5˚C) sterile rodent Ringer’s solution
with glucose bubbled with 100% oxygen. Hippocampi were sliced into sagittal sections
and transferred into PIPES-buffered saline (120 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1
mM MgCl2, 25 mM ᴅ-glucose, 20 mM piperazine-N,N’-bis[2-ethanesulfonic acid], pH
7.0 with NaOH). The superior region of the hippocampi was isolated to reduce
heterogeneity of cultured neurons. The superior region was further cut into 1 mm3
sections and placed in a sterile 3 mL glass vial. 1 mL of 0.5% trypsin and 0.01% DNase I
(Sigma-Aldrich, St. Loius, MO) in PIPES-buffered saline was added to the vial. Tissue
was incubated at room temperature for 30 minutes with 100% oxygen blown over the top
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of the solution to allow the trypsin to permeate the tissue. A second incubation at 37˚C
for one hour followed, to maximize the proteolytic activity of the enzyme. The tissue
was rinsed with 1 mL trypsin inhibitor solution (1 mg/mL trypsin inhibitor, Type II-O:
chicken egg white (Sigma-Aldrich, St. Louis, MO) and 1 mg/mL bovine serum albumin)
in rodent Ringer’s solution, then rinsed with Neurobasal-A growth media fortified with
B27 supplement (Life Sciences, Carlsbad, CA), 0.5 mM glutamine and 0.02 mg/mL
gentamicin. The tissue was placed in 1 mL fresh growth media and vigorously triturated
with a fire-polished Pasteur pipette. For electrophysiological experiments cells were
plated on 35 mm sterile culture dishes previously coated with poly-ʟ-lysine (MW 38,500
– 60,000, Sigma –Aldrich, St. Louis, MO) dissolved in 0.15 M boric acid (pH 8.4 with
NaOH), as described in Mynlieff (1997). For calcium imaging experiments, cells were
plated on a glass 22x22 mm coverslip coated with poly-ʟ-lysine. For confocal imaging
experiments, 75 μL of cell culture suspension was placed onto the poly-ʟ-lysine-coated
glass center of a modified plastic cell culture dish (MatTek Corporation, Ashland MA).
Neurons settled at the bottom of the dish before adding 1 – 2 mL of fresh media per dish.
Dishes were then placed in a 5% CO2 water-jacketed sterile incubator maintained at 37˚C

Figure 2.1: Appearance of neurons in
culture after 24 hours. Cells appear
spherical and many have begun to
display
characteristic
branched
morphology. Bright field image taken at
40x magnification. Scale bar = 20 µM.
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for 24 –48 hours (Figure 2.1).
The use of cultured neurons within 20 – 24 hours for electrophysiological
recording provides time for reinsertion of channels and receptors that may have been
sheared off during enzymatic and mechanical digestion. Furthermore, process outgrowth
is minimized, allowing for voltage control over the entire cell and preventing space clamp
problems characteristic of electrophysiological recordings performed on neurons with
long processes. Previous data from the laboratory showed that neurons in culture are still
able to fire and display characteristic electrophysiological properties after enzymatic and
mechanical digestion (Mynlieff 1997; Mynlieff 1999). Importantly, the U-tube delivery
system of pharmacological compounds provides a means to apply compounds to a much
smaller group of cells minimizing exposing the rest of the population of neurons to these
compounds in the same culture dish.
One advantage to calcium imaging versus electrophysiology its high throughput.
Electrophysiology samples only one cell at a time, whereas data acquisition via calcium
imaging allows for measuring calcium influx in up to 50 cells per capture. A second
advantage of calcium imaging is that cells with growing processes can easily be included
in recordings. This is more difficult in electrophysiological experiments because of space
clamp problems in cells with long axons or dendrites. Thus, while electrophysiology
provides a much more accurate temporal resolution, calcium imaging offers some distinct
advantages when used to measure calcium influx.
Culturing neurons for confocal microscopy allows the experimenter to treat with
various compounds, then fix the cells in order to understand changes that those
compounds may have caused. For example, activation of GABAB receptors is thought to
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mobilize PKC and cause its translocation from the cytosol to the membrane of the
neuron. By adding GABAB agonist baclofen to the culture and fixing it immediately, the
movement of PKC can be assayed via immunostaining. This type of direct application
and image analysis is more difficult in a slice, where pharmacological treatment will
likely not reach all neurons in the slice. Furthermore, the detail of changes occurring
within a single cell in isolation is easier to resolve than examining the changes of a single
cell within a densely populated hippocampal slice.
The use of hippocampal cell cultures isolated from postnatal rats provides a useful
system to study a GABAB receptor-mediated response. While embryonic cultures
contain a large percentage of excitatory pyramidal neurons, postnatal cultures contain a
greater percentage of GABAergic interneurons. Indeed, cultures from a 7 day postnatal
rat showed 41.8 ± 5.0% of the neurons were immunoreactive for anti-GABA antibodies,
suggesting these cells were inhibitory interneurons (Mynlieff 1997). A complication of
working with primary hippocampal cultures is that there is no way to select for cell type
specificity. For example, there are at least 16 types of inhibitory interneurons based on
electrophysiological and immunocytochemichal profiles, as well as a large percentage of
pyramidal neurons; in either calcium imaging or electrophysiology, it cannot be
determined what type which type neuron is being examined without post-recording
immunolabeling or single cell PCR.

Protein preparation and Western blotting
To prepare protein samples for Western blot analysis, whole hippocampal tissue
samples were isolated from P6-P8 rats by sacrificing the rat and excision of the
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hippocampus as described above, followed by homogenization of the tissue in ice-cold
sucrose buffer (250 mM sucrose, 10 mM Tris, 10 mM HEPES, 1 mM EDTA, pH 7.2)
with fresh protease inhibitors (1 ug/mL leupeptin, 0.5 mg/mL pepstatin, 0.5 mg/mL
Pefabloc, Sigma-Aldrich, St. Louis MO). To isolate membrane-bound proteins,
homogenized tissue was centrifuged at 3,622 x g for 10 minutes at 4˚C, followed by
centrifugation of the supernatant at 39,104 x g for 30 minutes. The pellet from this
centrifugation step was resuspended in sucrose buffer with protease inhibitors and stored
at -80˚C until samples were analyzed via Western blot. In order to prepare cell culture
samples for Western blot analysis, hippocampal cultures were obtained from 8 rats,
yielding 24 dishes. Each dish was rinsed twice in ice cold phosphate buffered saline
(PBS, 134.4 mM NaCl, 4.36 mMKCl, 10.56 mM Na2HPO4, 1.66 mM Na2H2PO4, pH 7.4
with HCl). 1 mL of sucrose buffer with protease inhibitors was added to each of the 24
dishes, neurons were scraped from the dishes, and the suspension was centrifuged at
30,427 x g for 10 minutes. The pellet was resuspended in sucrose buffer with protease
inhibitors and spun at 3,622 x g for 10 minutes. The supernatant was spun a final time at
48,497 x g for 30 minutes. The resulting pellet was resuspended in 30 µL sucrose buffer
with protease inhibitors and stored at -80˚C until samples were analyzed by Western blot.
To increase protein yield in the preparations, in certain experiments the cytosolic and
membrane fractions were separated using ultracentrifugation based on a protocol from
Wang et al., (2003). Cells were washed in Wang’s buffer (20 mM Tris, 2.5 mM EGTA, 1
mM EDTA, 100 mM NaF, pH 7.5 with HCl). Protease inhibitors listed above were
added, plus 2 mM dithiolreitol after 2 rinses in Wang’s buffer. The neurons were scraped
and spun at 30,427 x g for 8 minutes. The pellet was resuspended in Wang’s buffer and
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spun at 4,492 x g for 10 minutes. The supernatant was collected and spun at 100,000 x g
for 45 minutes. After this spin, the supernatant was collected and retained as the cytosolic
fraction. The pellet was resuspended once more in Wang’s buffer plus 0.1% Triton-X
100. The suspension was spun at 30,427 x g for 15 minutes, and the supernatant was
retained as the membrane fraction. All spins were done at 4˚C. Protein concentrations
were measured with a biophotometer (Eppendorf North America, Hauppauge NY).
NuPage lithium dodecyl sulfate sample buffer (Life Sciences, Grand Island, NY)
and reducing agent (500 mM dithiothreitol in PBS) were added to protein preparations
and heated to 70˚C for 10 minutes. Preparations were run on a 12% Bis-Tris Novex
Minigel® (Life Sciences, Grand Island, NY). Proteins were transferred onto a
polyvinylidene difluoride membrane with a pore size of 0.45 µM. Membranes were
washed for 5 minutes with PBS, then blocked for 1 hour with PBS plus 0.05% Tween,
5% nonfat dry milk, and 0.1% bovine serum albumin at room temperature. The
membranes were decorated with primary antibodies added to the PBS blocking solution
by rocking them overnight at 4˚C using antibodies listed in Table 4. Membranes were
then brought to room temperature, rinsed in PBS with 0.05% Tween, and probed with
either goat anti-rabbit or goat anti-mouse horseradish peroxidase conjugated secondary
antibody (table 4) for 90 minutes at room temperature. The secondary antibodies were
rinsed from the membrane with PBS and 0.05% Tween, protein bands were visualized on
classic blue autoradiography film (Molecular Technologies, St. Louis, MO.) after a 5
minute exposure to SuperSignal West Dura Extended Duration chemiluminescent
substrate (Pierce, Rockford IL).
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Primary Antibody

Source

Host Species

Dilution

Application

Gαq alpha subunit

Genetex

Rabbit

1:500; 1:1000

Gα11 alpha subunit
α/β tubulin

Genetex
Cell Signaling
Technologies
Neuromab

Rabbit
Rabbit

1:1000
1:2000

Western blot;
immunostaining
Western blot
Western blot

Mouse

1:1000

Immunostaining

Hybridoma
Bank

Mouse

1:2000

Immunostaining

Source

Species

Dilution

Application

ThermoPierce
ThermoPierce
ThermoPierce

Goat-Anti
Rabbit
Goat-Anti
Mouse
Goat-AntiRabbit

1:1000-1:2000

Immunostaining

1:1000-1-2000

Immunostaining

1:2000-1:2500

Western blot

GABAB receptor
B1 subunit
GAD-6

Secondary
Antibody
Dylight 488
Dylight 550
HRP-conjugated

Table 4: List of primary and secondary antibodies used in experiments.

To quantify protein visualized via Western blotting, the integrated optical density
(IOD) of each band was measured using Labworks 4.6 software (UVP, Inc., Upland CA).
To control for gel loading, each lane was loaded with the same amount of protein as
determined by measurement on a biophotometer. This was further controlled for by
dividing the IOD for each protein of interest by the IOD of a control antibody (α/βtubulin, Table 4) in the same lane. At least two separate samples were analyzed for each
experiment.
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Figure 2.2: Image of cultured cells after 24 hours loaded with ratiometric Fura-2 AM dye.
(Left) field of cells under nonstimulating conditions. (Right) same field of cells stimulated
with 50 mM KCl show characteristic change in fluorescence.

Calcium Imaging
Cultured neurons on glass coverslips were incubated in 5 μM Fura-2
acetoxymethyl ester (Fura-2 AM, Life Technologies, Carlsbad CA) in calcium imaging
Ringer’s solution (CIR, 154 mM NaCl, 5.6 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM
HEPES, 11 mM glucose, pH 7.4 with NaOH) for 1 hour at room temperature in the dark.
Cells were rinsed and incubated for 30 min at room temperature in CIR without Fura-2
AM to allow for de-esterification. Depolarization was induced by perfusion with high
potassium solution (100 mM NaCl, 50 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM
HEPES, 11 mM glucose, pH to 7.4 with NaOH) for 30 seconds to open voltage-gated
calcium channels (Figure 2.2). Throughout experiments, CIR was continually perfused at
a rate of 2 mL/minute. Application of high KCl and/or pharmacological agents were
perfused at approximately 3 pSi, producing perfusion at a rate greater than 5 times that of
CIR perfusion.Each experiment consisted of an initial perfusion of KCl alone, followed
by coapplication of KCl and pharmacological agents (Table 5). A final KCl stimulation
was performed after drug treatment. The initial and final KCl responses were averaged
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and compared with the response of KCl plus pharmacological agents. These agents were
perfused onto the cells for 15 seconds before addition of high KCl solution. Cells were
excited at 340 and 380 nm, and emissions were measured at 510 nm using Slidebook 5.0
software (Intelligent Imaging Innovations, Denver CO). The ratio of the emissions
intensity when Fura-2 is excited at 340 and 380 nm is directly correlated to changes in
intracellular calcium (Grynkiewicz et al., 1985). Control experiments were performed in
which the cell was stimulated 3 consecutive times with KCl. The initial and final
responses were averaged together, and compared with the middle response. This allowed
for determination of inherent variability within the system. The standard deviation for
the middle response, compared to the average of the initial and final responses, was
±11.20%. In order for a cell to be classified as “increasing” or “decreasing” in response
to 10 µM baclofen treatments during depolarization, a neuron had to show a response of
± 21.4% that of KCl controls, which represented two standard deviations from control
values. Average data represent the mean ± SEM.

Confocal imaging
Whole hippocampi from P6-P8 rats were excised and fixed in 4%
paraformaldehyde for 30 minutes at 4˚C. Hippocampi were cryoprotected in PBS
solution containing 30% sucrose for 90 minutes at 4˚C. The tissue was embedded in
optimal cutting temperature mounting medium (OCT, Sakura Finetek, Torrance, CA) and
frozen on dry ice. 20 µM transverse sections were sliced on a cryostat and placed on
glass slides. Hippocampal sections were permeabilized in PBS with 0.5% Triton X-100
for 20 minutes, then blocked for nonspecific binding with 10% goat serum (Life
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Sciences, Carlsbad, CA) in PBS with 0.05% Triton X-100 for 60 minutes. Primary
antibodies were made in PBS with 0.05% Triton X-100 and 0.1% goat serum and were
incubated with the sections for 2 hours at room temperature. A list of primary antibodies
used can be found in table 4. After incubation, sections were rinsed 3 times in PBS
before addition of Dylight 488- and 550-conjugated secondary antibodies (Thermo
Scientific, Rockford IL) for 1 hour. (See Table 4 for specific dilutions and sources.)
After another 3 rinses, mounting medium with 4,6 diamidino-2-phenylindole (DAPI,
Vector Laboratories, Burlingame, CA) was applied, slides were covered with a glass
coverslip and sealed.
For preparation of cultured cells for confocal analysis, a similar procedure was
followed except as noted here. Cells grown on tissue culture dishes modified with glass
bottoms were fixed with 4% paraformaldehyde after removal of neurobasal A growth
media. Fixed cells were rocked with primary antibodies overnight at 4˚C before
decoration with secondary antibodies (See Table 4).
Images were acquired on a Nikon Perfect Focus Ti-E confocal microscope and
were analyzed on NIS Elements imaging software (Nikon Instruments, Melville, NY).
To determine colocalization in slices, regions of interest (ROIs) were selected from areas
within the stratum oriens, pyramidal cell layer, stratum radiatum, and dentate granule cell
layer. Prior to quantification, background fluorescence was removed by measuring
brightness of each fluophore in preparations not treated with primary antibodies, then
subtracting that brightness value from that of experimental slides. The Pearson
correlation coefficient (PCC) was determined for each region to quantify the degree of
colocalization between Gαq and GABAB receptors in each region. A higher PCC is

39
suggestive that proteins of interest are located in close proximity. PCC values were
averaged by region, then compared via one-way ANOVA. When acquiring images to
average and compare, microscope settings (scan speed, pinhole size, laser intensity) were
not changed to allow for comparison across different preparations.

Electrophysiology
Calcium currents were measured using whole cell patch clamp electrophysiology
in voltage clamp mode. Currents were collected using a Dagan 3900A patch clamp
amplifier (Dagan Corporation, Minneapolis, MN), Digidata 1322 data acquisition system,
and pClamp 9.0/10.0 software (Molecular Devices, Sunnyvale, CA). Recording
immediately after dissociation minimizes space clamp problems, but in order to let the
neurons recover from digestion and allow for sufficient knockdown, experiments were
performed 24-48 hours after dissection. A Flaming/Brown P-87 Micropipette Puller
(Sutter Instrument Co, Novato, CA) was used to pull electrodes of 4-10 MΩ from
borosilicate glass capillary tubes. Pipettes were filled with internal solution (140 mM Csaspartate, 5 mM MgCl2, 10 mM Cs2EGTA, 10 mM HEPES, 2 mM ATP-Na2, 0.1 mM
GTP, pH 7.4 with CsOH and osmolarity of 310 – 320 mOsm); neurons were kept in
extracellular solution (10 mM CaCl2, 145 mM TEACl, 10 mM HEPES, 1 µM
tetrodotoxin (Tocris Bioscience, Bristol, United Kingdom), pH 7.4 with CsOH and
osmolarity 300 – 310). Whole cell currents were electronically filtered at 1 kHz and
digitized at 2 kHz. Linear components of leak current were subtracted post-hoc by the
passive resistance protocol in the pClamp 9.0/10.0 software.
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To study drug effects on maximally achieved calcium currents, neurons were
depolarized for from -80 mV to +10 mV for 300 ms. Analysis was performed during the
last 50 ms of this pulse (the sustained component of the calcium current) to maximize the
contribution of L-type (long
lasting) current to total current
(Figure 2.3). However, it is
likely that there is contribution
from the other types of HVA
currents (P/Q-type, N-type, Rtype), despite work showing that
these channels inactivate much
faster (τ = 50 – 80 ms versus τ >
500 ms for L-type calcium
Figure 2.3: (Top) Typical calcium current trace elicited,
containing both a peak and sustained component.
(Bottom) Depolarizing pulse given for 300 ms from -80
to +10 mV.

current (Tsien et al., 1988). In
certain experiments, to reveal
primarily L-type current, P/Q-

type and N-type current were blocked with application of 1 µM ω-conotoxin MVIIC
(IC50 = 40 nM, (Gandia et al., 1997). To examine the current-voltage relationship with
and without baclofen, neurons were held at -80 mV and depolarized by a series of 10 mV
steps from -50 mV to +50 mV. For electrophysiological studies, various drugs were
applied on the order of seconds via U-tube delivery system. The U-tube was constructed
of PE-10 polyethylene tubing housed in glass tubing, which allows for both rapid
application and washout of pharmacological agents in an acute area. Fast Green FCF
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(Sigma-Aldrich, St. Louis, MO) was added to the drug solution to visualize delivery.
Table 5 contains concentrations of drugs used as well as their targets.
The core of research done in the Mynlieff laboratory is understanding how 10 µM
baclofen, a GABAB-specific agonist, enhances L-type calcium current. Since calcium
currents often demonstrate either run-up or run-down in their current, multiple control
depolarizations were given whenever possible. In order to characterize the response of
neurons as either “increasing,” “decreasing,” or “no change” in their calcium currents,
control pulses were given before application of baclofen, and again after washout.
Control currents were plotted and a linear regression line was generated based on those
controls, as well as a 95% confidence interval of this regression line. Neurons treated
with baclofen were categorized based on where they fell with respect to the 95%

Figure 2.4:
Representative
linear
regression trace with
95% confidence interval
constructed. In this case,
treatment with the drug
(red diamonds) leads to
currents that fall outside
the confidence interval
constructed from control
pulses (black circles),
suggesting a significant
effect of the drug.

confidence interval. Furthermore, at any timepoint when pharmacological agents were
applied, the linear regression equation allowed for calculation of an “expected” current
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(that which would be expected if the agent were not present). This could then be
compared with actual current when the agent was present (Figure 2.4)
Analysis of current-voltage (IV) data consisted of creating IV curves to describe
L-type current at various voltages in either neurons treated with 10 µM baclofen or
controls. Conductance values were calculated at each voltage step by dividing peak
current elicited by the driving force. Driving force is the difference between the neuron’s
membrane potential and the reversal potential for an ion. It is defined by the equation
Iion = gion(Vm – Eion), where Vm – Eion is the driving force. Conductance plots were
generated to examine whether there was a shift in the activation voltage (voltage that
causes channels to begin to open and current to be measured) or voltage that elicits half
maximal current (V1/2) in those neurons treated with baclofen.

Pharmacological Source
Agent
RS-Baclofen
SigmaAldrich
ω-Conotoxin
SigmaMVIIC
Aldrich
Nimodipine
Nifedipine
CamKIIntide
Ant-AIP-2
CK59

SigmaAldrich
SigmaAldrich
EMDMillipore
EMDMillipore
EMDMillipore

Concentration Pharmacological
Activity
10 μM
Activate GABAB
receptors
1 μM
Block N- and P/Qtype calcium
channels
20 μM
Block L-type
calcium channels
20 μM
Block L-type
calcium channels
250 nM
Inhibit CaMKII
signaling
50 nM
Inhibit CaMKII
signaling
Various
Inhibit CaMKII
signaling; block
voltage-gated
calcium channels

Table 5: Listing of pharmacological agents used in various studies

IC50/EC50
2.8 μM
40 nM
140 nM – 2.7
μM
3 μM
50 nM
4 nM
>10 μM for
CaMKII; 52
μM for
calcium
channels
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Protein knockdown with morpholinos
In order to selectively knock down proteins of interest, morpholinos (Gene-Tools
LLC, Philomath, OR) were used to prevent translation of mRNA. Morpholinos (MO) are
synthetic 25 amino acid-long oligos that are designed to bind near the start codon of
specific mRNA. This binding prevents association of the translational machinery to the
mRNA, thus yielding decreased protein. Morpholinos have several advantages over
more traditional siRNA-mediated knockdown. First, because they are synthetic, MO are
not subject to enzymatic degradation that often break down siRNA over time. Second,
they achieve a highly specific knockdown, in contrast to siRNA mediated knockdown in
which off target effects may occur. Finally, successful siRNA mediated knockdown in
primary neuronal cultures has proven more difficult than in other cell types. Thus, the
use of MO to achieve protein knockdown represents a viable and innovative alternative to
more commonly used knockdown methods.

Figure 2.5: Mopholinos penetrate the cell and prevent
translation. (Right) The Endo Porter peptide binds the
MO cargo and is taken into the cell in an endocytosis
mediated process. (Top) Once inside, the MO binds to
the targeted mRNA near the start codon, sterically
inhibiting the initiation complex from associating, thus
preventing translation of the mRNA.
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Morpholinos were introduced to cell cultures immediately after plating. In order
for the cell to take up the MO, the MO were cotransfected with EndoPorter, a proprietary
peptide that brings “cargo” into the neurons via an endocytosis-mediated process.
Control experiments were done with a variety of EndoPorter concentrations (2-10 µM) to
ensure there were no cytotoxic effects. Delivery of MO was assessed using MO with a
carboxyfluorescein tag fused to its 3’ end, then examined with fluorescent microscopy.
The sequence of the morpholino designed to knock down Gαq was 5’
ACGCCATGATGGACTCCAGAGTCAT3’; it was delivered at a concentration of 2 µM
together with 4 µM EndoPorter. Because G-proteins are known to have a relatively long
half-life (Derrien et al., 1996), Western blot experiments were done to assay knockdown
at both 24 and 48 hours post transfection. Control experiments were done on cell cultures
treated with either a nonsense MO (5’ AGCCAACGCCCCAATGATTCTGACT3’) or
cultures treated with EndoPorter only.
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CHAPTER 3

Demonstration of enhanced calcium entry upon GABAB receptor activation with

ratiometric calcium imaging and examination of IV relationship in cells that do not

demonstrate current enhancement

INTRODUCTION

During early neonatal development, neuronal GABA receptors have been
extensively studied. However, a large proportion of these studies involve the ionotropic
GABAA receptor. GABA is considered the main inhibitory neurotransmitter in the
mature mammalian nervous system; when GABA binds to its GABAA receptor, the
receptor passes negatively charged chloride ions inward. This hyperpolarizes the neuron,
and dampens excitability. However, in the developing nervous system, the chloride
gradient is reversed, and GABAA receptor activation will allow for chloride efflux.
Negative charge is lost from the cell, and this depolarization increases the cell’s
excitability (for review, see Ben-Ari 2002. Thus, there have been a multitude of studies
examining this switch in chloride currents and changes in GABAA receptor function
(Hutcheon et al., 2000; Banks et al., 2002; Bray and Mynlieff 2009; Holter et al., 2010;
Kilb 2012).
The development of the metabotropic GABAB receptor is less well-defined.
GABAB-mediated potassium currents can be consistently recorded after the first postnatal
week (Gaiarsa et al., 1995), and protein expression reaches adult levels after the second
postnatal week (Lopez-Bendito et al., 2004). It has been suggested that GABAB
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receptors do not undergo a major functional alteration during development (Kilb 2012).
However work in the Mynlieff laboratory shows a potentially unique function of these
receptors during the early neonatal period. Activated GABAB receptors mediate both an
increase and decrease in calcium current; furthermore, the increase in calcium current
was through L-type calcium channels, while the decrease was through N-type calcium
channels. This inhibition has been previously described as occurring through N-type
channels; the mechanism of inhibition has also been detailed. (Guyon and Leresche 1995;
Harayama et al., 1998; Sun and Chiu 1999; Colecraft et al., 2000). Conversely, when
Carter and Mynlieff (2004) described the enhancement of L-type current in neonatal
hippocampal cultures, there was only one report of GABAB receptors enhancing such
current in neurons, in the salamander retina (Shen and Slaughter 1999). Unlike the
inhibition of N-type channels, the mechanism of this enhancement had not been clearly
worked out. Subsequent research in the Mynlieff laboratory revealed this enhancement
to be a developmental phenomenon. The proportion of neurons that demonstrate an
increase in response to GABAB receptor activation increases until P7, then decreases at
P14 (Bray and Mynlieff 2009). Thus, data from the Mynlieff laboratory suggest there is
a specific function of GABAB receptors during development.
Understanding how neurons regulate calcium levels during development is
critically important, as calcium is a crucial intracellular messenger. Calcium influx can
regulate neuronal differentiation, excitability, synapse formation, and gene transcription
(for review see Lohmann 2009; Michaelsen and Lohmann 2010; Hagenston and Bading
2011). L-type current is thought to be more involved with these processes than with
neurotransmission. Therefore, deciphering the pathway by which GABAB receptor
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activation leads to increased intracellular calcium concentrations during neonatal
development may be critical in understanding how mature neuronal circuitry is
established.
The focus of this study was to provide further detail of the interplay between
GABAB receptors and L-type current. Previous studies in the Mynlieff laboratory used
whole-cell patch clamp electrophysiology to demonstrate L-type current enhancement
and N-type current attenuation. However, the throughput of electrophysiology is low, so
I sought to elucidate details of the pathway using the higher throughput method of
ratiometric calcium imaging. Before examining any component of the GABAB receptormediated response, it was necessary to demonstrate this phenomenon was not an artifact
of electrophysiological recording. Once calcium imaging was established as a viable
method, the source of the calcium increase was investigated. Calcium concentrations are
kept at low levels inside the cell, relative to extracellular concentrations. Calcium
concentrations within the endoplasmic reticulum are high as well. While it has been
shown that calcium current increases upon GABAB receptor activation, the contribution
of calcium released from intracellular stores (i.e. the endoplasmic reticulum) was not
known. Furthermore, in studies by Carter and Mynlieff (2004) and Bray and Mynlieff
(2009, 2011), enhancement of L-type current always required depolarization to activate
L-type channels. However, a recent report showed activation of GABAB receptors alone
was sufficient to increase intracellular calcium levels (Kuczewski et al., 2011). I
attempted to reproduce this effect to gain insight into a possible molecular mechanism for
this enhancement. Finally, since I also observed an attenuation of calcium entry in a
subset of cells, I sought to characterize the kinetic changes occurring, similar to how
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Carter and Mynlieff (2004) described the enhancing effect by examining the change in
activation voltage and conductance shift.
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RESULTS

Ratiometric calcium imaging detects changes in intracellular calcium upon GABAB
receptor activation
Previous studies in the Mynlieff laboratory have shown that cells treated with 10
µM baclofen may show changes in calcium current when these cells are given a
depolarizing pulse from -80 to +20 mV. Cells showed a distribution of responses, where
approximately 35% of neurons examined display attenuation of current, 25% of neurons
display enhancement of current, and 40% of neurons do not display a significant effect on
current. In order to examine whether this phenomenon could be demonstrated using
ratiometric calcium imaging, cells were loaded with a ratiometric dye (Fura-2 AM) for 1
hour (see methods). Instead of a depolarizing pulse, neurons were treated with a high (50
mM) potassium chloride (KCl) solution to induce depolarization. 10 µM baclofen, a
GABAB receptor-specific agonist, was preapplied for 15 seconds before the high KCl
solution, as well as during the stimulation. High KCl was perfused onto the cells first for
thirty seconds. After washout, baclofen and high KCl were coapplied. Following a final
washout KCl was applied once again. The two high KCl alone values were averaged and
compared with the middle (treatment) value.
Similar to electrophysiological data, calcium imaging data showed 3 distinct
responses to baclofen treatment. In initial studies, 25.7% of neurons showed increased
calcium entry; the average increase was 25.0%, compared to baseline calcium entry when
cells were depolarized with high KCl alone (not in the presence of baclofen). 48.0% of
cells showed a decrease in calcium entry, with an average decrease of 23.6%. Finally,
26.3% of cells did not respond to baclofen treatment with either an increase or a decrease
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in calcium entry. These early studies considered an increase or a decrease to be ± 5% of
control KCl values. However, it became clear that there was greater inherent variability
in response of control cells than the 5% cutoff being used. Thus, cells were stimulated
with high KCl three times. The middle stimulation was considered the “treatment” and
compared with the average of stimulations 1 and 3. These data showed that KCl alone
varied ± 10.7% from one KCl treatment to another (N = 127). Therefore, using a 5%
cutoff was not strict enough, and I could have been considering cells that varied based
only on KCl treatment. Experiments were repeated using a value of ± 21.4% (twice the
standard deviation of the control response) to be considered increasing or decreasing,
respectively. As expected, the more stringent criteria changed the distribution of
responses. 46 of 392 cells (11.73%) showed an increase in current entry, with an average
increase of 39.29 ± 2.54% (Figure 3.1a). 106 (27.04%) cells showed a decrease in
calcium entry, with an average decrease of 36.23 ± 0.96% (Figure 3.1b). Finally, 240
(61.22%) showed no change in calcium entry with the new, more stringent criteria
applied (Figure 3.1c). Though there were fewer cells that showed enhanced calcium
entry upon GABAB receptor activation than when examined with electrophysiology, there
was still a significant difference between controls and those treated with 10 µM baclofen.
These results validated the electrophysiological studies and suggested ratiometric calcium
imaging can be used as a tool to understand the activated GABAB receptor-mediated
response.
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C.

B.
Figure 3.1: Response to baclofen and high KCl
solution, as measured with ratiometric calcium
imaging. A: Neurons were depolarized with high
KCL for 30 s, then baclofen was applied for 15 s
before being coapplied for 30 s with high KCl. A
final high KCl treatment was performed after
baclofen washout. Representative traces of cells
that show an increase in calcium entry as a
response to treatment. Each line represents an
individual cell. B: Same as A, only this subset of
cells show a decrease in calcium entry. C:
Summary of cell responses, N = 342.

Increasing intracellular calcium concentration is due to influx from the extracellular
milieu
To determine the proportion of calcium that enters the cell through surface
calcium channels versus that which is released from intracellular stores, calcium imaging
was used, and the concentration of calcium in the perfusing solutions was adjusted.
Typically, the high KCl solution contains 10 mM calcium; when the cell is depolarized,
there is a gradient which causes the ions to flow inward from outside the cell. However,
the hypothesis of GABAB receptor activation is that it activates a pathway by which PIP2
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is cleaved. One cleavage product, IP3 can translocate to the endoplasmic reticulum (ER)
and activate IP3 receptors on the ER membrane. These activated receptors are permeable
to calcium, and thus the calcium sequestered in intracellular stores may be released.
Therefore, high KCl solution was made with calcium absent. When cells were stimulated
for 30 seconds with 0 calcium-containing high KCl and baclofen, there was no detectable
change (0.54 ± 2.59% increase) in intracellular calcium. However, when the same cells
were treated with 10 mM calcium-containing high KCl, the prototypical response (114 ±
94.84% increase) was seen (N = 88, Figure 3.2 and Table 6). These data suggest that the
majority of calcium influx is through voltage-gated channels, rather than through release
from intracellular stores.

Figure 3.2: When high KCl is applied to open voltage-dependent channels but calcium is
removed from the solution, no calcium entry is seen. These data suggest that the source of
calcium entry is from extracellular sources. The response is restored when calcium is added
back to the depolarizing solution and the rinsing solution.
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Treatment

50 mM KCl

Baseline
340/380
Ratio
0.42 ± 0.10

Peak
340/380
Ratio
0.88 ± 0.35

% change

114.74 ± 94.84

50 mM KCl with 0 mM Ca2+,
10 µM Baclofen

0.44 ± 0.11

0.44 ± 0.10

0.54 ± 2.59

Table 6: Summary of cellular responses when depolarized with high KCl with or without
calcium present in solutions. Data represent mean ± SEM.

Given that 10 µM baclofen did not cause an increase in intracellular calcium
when no calcium was present in the extracellular solution and voltage-gated channels
were open, it seemed unlikely that stimulation of GABAB receptors without
depolarization would lead to change in intracellular calcium. However, it has been
reported that increased concentrations (50 µM) of baclofen were sufficient to induce an
increase in intracellular calcium in P0 hippocampal cultures (Kuczewski et al., 2011),
thought to be caused by the pathway mentioned above. I used the same 50 µM
concentration of baclofen and attempted to replicate these data; cells treated with KCl
alone averaged a 144 ± 90.16% increase in intracellular calcium compared to baseline
levels. The same cells averaged a 1.95 ± 4.74% change when 50 µM baclofen was
applied (N = 68, Table 7). This result agrees with the data mentioned previously, that
changes in intracellular calcium require opening of voltage-gated channels and
extracellular calcium to be present. Furthermore, activation of GABAB receptors alone,
even at high concentrations, cannot induce a change in intracellular calcium.
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Treatment
50 mM KCl
50 µM Baclofen

Baseline 340/380
ratio
0.31 ± 0.04
0.31 ± 0.05

Peak 340/380 ratio

% change

0.79 ± 0.37
0.32 ± 0.05

144.32 ± 90.16
1.95 ± 4.74

Table 7: Summary of responses seen in cells depolarized with high KCl, or treated with GABAB
agonist baclofen alone

Attenuation of calcium current does not shift activation voltage or conductance of
calcium channels
While much of the focus of my work has been to detail mechanisms responsible
for the enhancement of intracellular calcium upon GABAB receptor activation, there is a
proportion of neurons that undergoes a reduction of intracellular calcium under the same
conditions. The inhibitory response seen when baclofen is applied can be abolished by
ω-conotoxin GVIA, suggesting it is specifically N-type channels that are inhibited (Carter
and Mynlieff 2004). A more detailed kinetic analysis was performed on the neurons that
demonstrated current enhancement, which showed that GABAB receptor-mediated
increases in L-type current caused a decrease in the voltage at which the L-type channel
begins to pass current, as well as a leftward shift in the conductance. This study did not
examine similar parameters of N-type inhibition. When N-type channels were inhibited
by G protein-coupled δ-opioid receptor activation or by neurotransmitters norepinephrine
and somatostatin, inhibition was mediated through a slowing of activation kinetics; the
peak component of the current developed significantly slower than controls (Golard and
Siegelbaum 1993; Toselli et al., 1999). GABAB-mediated N-type inhibition has been
examined, and similar to N-type inhibition in other systems, voltage-dependent inhibition
develops due to a slowed activation phase of the peak current (Tatebayashi and Ogata
1992). However, none of these studies examined whether the activation voltage of these

55
calcium channels were affected. Thus, the focus of this study was to examine whether Ntype inhibition shifted activation voltage such that a stronger depolarization is required to
pass current.
To determine whether activation voltage is shifted in cells that demonstrate
attenuation of calcium current, neurons were held at -80 mV. Pulses 300 ms in duration
were given from -50 mV to +50 mV in 10 mV steps. 10 µM baclofen was applied after
control currents were elicited. After currents were measured in the presence of baclofen,
the drug was washed out and another group of currents was collected. Since cell cultures
contain a heterogeneous mix of neurons, each cell has a different array of voltage-gated
calcium channel types. However, the maximal activation voltage of these currents was
always between +10 mV and +20 mV. In order to determine a cell’s response to baclofen
treatment, peak current was measured at +20 mV in the presence and absence of
baclofen, as well as after washout. A linear regression line of control values was
constructed, to account for run up or run down commonly seen with calcium channel
recordings. A 95% confidence interval was constructed, and the experimental value

Figure 3.3: Linear regression
line constructed from control
300 ms depolarizing pulses
(black dots) surrounded by
95% confidence interval.
Baclofen application (red
diamond) is outside the
confidence interval and is
therefore
considered
as
having a significant effect.
Inset: raw trace containing
values used to construct linear
regression line. Blue line:
control; red line: baclofen
application;
black
line:
washout.
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plotted. If the experimental value was below the linear regression line and outside the
confidence interval, it was considered to show attenuation of current (Figure 3.3).
Full current-voltage (IV) relationships of neurons that showed this reduction of
current or those that showed no change (experimental fell within the 95% confidence
interval) were constructed (Figure 3.4). The voltage at which channels begin to display
current was derived from these measurements. Furthermore, conductance values were
calculated by dividing peak current by the driving force. Conductance plots were
constructed and the voltage was measured when the neuron reached half-maximal
conductance (V1/2). The V1/2 for cells that do not show a difference in calcium current
when GABAB receptors are activated is 8.3 ± 1.4 mV, compared to 8.2 ± 1.2 mV in
controls (N = 15). The V1/2 for cells that display attenuation of calcium current is 9.8
mV, compared to 8.5 mV in controls (N = 2, Figure 3.5). Baclofen application did not
significantly shift a cell’s activation voltage compared to its value before or after
treatment. These data suggest N-type channel inhibition is not due to a change in
activation voltage or whole cell conductance; more likely it is the slowed activation phase

Current (pA)

Voltage (mV)

Figure 3.4: Current-voltage
(IV) relationship in a neuron
that demonstrates attenuation
of current when treated with
baclofen. The peak component
of calcium current was
measured during the 300 ms
depolarizing pulse. The cell
was held at -80 mV, and
voltages were increased +10
mv from -50 to +50 mv. There
is no shift in the IV curve when
current is attenuated (red trace).
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and voltage-dependent inhibition suggested by Tatebayashi and Ogata (1992).

Figure 3.5: Activation curve of peak
current in a neuron that demonstrates a
decrease in response to baclofen
application. Data were fit with a 3parameter
sigmoidal
equation.
Conductances were normalized at each
test potential by dividing the
conductance at each test potential by
the maximal conductance obtained for
that cell. Half-maximal activation
voltage (V1/2) was calculated for each
individual cell.
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DISCUSSION
GABAB receptor-mediated enhancement of L-type current was a phenomenon
first described with the use of electrophysiology (Shen and Slaughter 1999). Since then,
the Mynlieff laboratory has confirmed this finding in the developing mammalian system,
also using electrophysiology (Carter and Mynlieff 2004; Bray and Mynlieff 2009; Bray
and Mynlieff 2011). However, while electrophysiology can provide much faster
temporal resolution, its throughput is limited. Thus I showed that calcium imaging can
similarly be used to demonstrate this effect. It is important to note that calcium imaging
does not measure calcium current directly; instead it measures a difference in fluorescent
states of a specific fluorophore. The key to ratiometric imaging is that by using a dual
wavelength fluorophore, not all cells are required to take up exactly the same
concentration. For example, Fura-2 AM is excited at 340 nm when not bound to calcium;
in its bound state, it is excited at 380 nm. Thus, the response of changing levels of
fluorescence is simply a difference in ratio between free Fura-2 AM and Fura-2 AM
bound to calcium in any given cell. As calcium enters, more calcium becomes bound by
the Fura-2 AM, such that a change in fluorescence is actually a change in ratio 340 to 380
ratio; this serves as an indirect measure of calcium entry. Another concern regarding
fluorescence measurements is that since the volumes within individual neurons in culture
is unequal, one is only capturing data on a specific plane. If the plane is not the same,
light intensity may vary from one compartment to the other. Using a dual length
fluorophore like Fura-2 AM alleviates this issue. For example, a neuronal cell body may
be more round, and its associated dendrite will be relatively flatter. Since the ratiometric
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imaging is always comparing bound to free Fura-2 AM, any region of interest will always
be compared to itself, dendrite to dentrite, or cell body to cell body.
It is also likely that calcium imaging does not have as much experimental bias as
does electrophysiology. When performing calcium imaging, all cells are examined,
regardless of size, morphology, etc. Only if they are unhealthy are they not included in
data analysis. For example, a cell whose calcium levels do not return to baseline after
high KCl is washed out will not be included in analysis, because it is likely not healthy
enough to extrude calcium. Electrophysiological recording allows the experimenter to
pick the cells from which he or she records. This artificial selection may not reflect the
actual makeup of cells in culture. One concern of data presented here is that the
proportion of cells that demonstrate enhancement of calcium entry is approximately half
of that seen in electrophysiology. This is likely due to experimental bias. Because
calcium imaging is likely a better representation of the all cell types in the culture, it is
possible that enhancement measured here is more accurate than what is observed with
other methods. Thus, while calcium imaging does not provide the fast temporal
resolution of whole cell patch clamp recording, it has numerous advantages and can be
used to show similar effects as electrophysiology.
Our laboratory and others that GABAB receptor activation can lead to increased
levels of intracellular calcium (Shen and Slaughter 1999; Carter and Mynlieff 2004; Bray
and Mynlieff 2009; Bray and Mynlieff 2011; Park et al., 2010; Kuczewski et al., 2011;
Mitzuta et al., 2011; Im and Rhim 2012). However, despite this phenomenon being
described several times, the mechanism responsible for enhanced calcium levels remain
unknown. One hypothesis is that the behavior of the channel is modified, such that it
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passes more current. An example of this possibility is that phosphorylation of the
channel could lead to its being open for longer periods of time. A second hypothesis is
that activation of GABAB receptors leads to activation of PLCβ, generation of IP3 after
cleavage of PIP2, and opening of calcium-permeable IP3 receptors on the endoplasmic
reticulum. If this hypothesis is correct, activation of GABAB receptors alone should
induce increases in intracellular calcium levels. However, data presented here show
applications of GABAB agonist baclofen resulted in no change in intracellular calcium
levels when cells were not depolarized. When calcium channels were activated but no
calcium was present extracellularly, baclofen still failed to cause an increase in
intracellular calcium levels. These data are in agreement with previous data in the lab
that enhanced calcium concentration is through L-type calcium channels. Kuczewski et
al., (2011) was able to block baclofen mediated calcium enhancement by inhibiting Ltype channels. This is particularly interesting because in this study, cells were never
depolarized, suggesting some novel mechanism whereby L-type channels are activated
by the GABAB response. Perhaps a more plausible scenario is that activation of GABAB
receptors initiates a signal transduction cascade that leads to modulation of L-type
channels, such that they can allow more calcium into the cell. This hypothesis is
supported by data from Carter and Mynlieff (2004) which shows that L-channels activate
at more hyperpolarized potentials in the presence of baclofen. It is possible that other
kinetic changes underlie observed enhancement as well. Changes in open probability or
mean open time of the channels due to a phosphorylation event could lead to increased
concentrations of calcium; single channel recording would be required to examine this
hypothesis.
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In addition to observing enhancement of calcium entry when performing calcium
imaging, a subset of cells also demonstrated reduced calcium entry. This finding was
previously demonstrated in our laboratory, and characterized pharmacologically as
inhibition of N-type calcium channels (Carter and Mynlieff 2004). I conducted studies
that characterized the current-voltage relationship of neurons that demonstrate attenuation
of N-type current, as well as those neurons whose current is not changed. The purpose
was to examine whether these cells displayed a shift that may help explain how baclofen
affects calcium channels. Not surprisingly, I found there is no change in activation
voltage or V1/2. The closely related P/Q-type channel is similarly inhibited by GABAB
receptor activation, by the same mechanism as N-type channels. When the IV curve for
P/Q-channel inhibition is shown, activation voltage does not change (Mintz and Bean
1993). Furthermore findings by (Carter 2002) showed only a slight leftward shift in the
IV curve of cells that showed attenuation when exposed to baclofen; there was no
significant difference in the activation voltage of these cells. My work essentially
repeated these studies and led to the same conclusion. The most plausible hypothesis is
that current develops more slowly due to the slowed activation phase of the N-type
channel and characteristic voltage-dependent inhibition of these channels (Tatebayashi
and Ogata 1992).
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CHAPTER 4

The signaling pathway involved in GABAB receptor activation-mediated

increases in L-type calcium current

INTRODUCTION

GABAB receptor activation is most commonly linked to a response that decreases
a neuron’s excitability. Upon ligand binding, there are three well described inhibitory
mechanisms. First is inhibition of voltage gated N- and P/Q-type calcium channels.
Presynaptic inhibition leads to decreased release of neurotransmitter, while postsynaptic
inhibition decreases dendritic calcium spikes. Second is activation of GIRK channels.
When GIRK channels are active, potassium ions move out of the neuron, generating slow
inhibitory postsynaptic potentials (IPSPs). Finally, GABAB activation decreases
phosphorylation of target proteins due to reduced protein kinase A (PKA) activity. The
G protein α subunit mediates the decrease in PKA activity through a signal transduction
cascade; adenylate cyclase is inhibited from producing cyclic AMP (cAMP). Without
cAMP, PKA remains catalytically inactive. It is the G protein βγ subunits which mediate
the decrease in N- and P-Q current as well as GIRK current. Importantly, whether it is
the α or βγ subunits which decrease excitability, GABAB receptors have always been
linked with Gαi/o G proteins.
A less well described phenomenon is the enhancement of L-type calcium current
upon GABAB receptor activation. This GABAB mediated increase in L-type current has
been suggested to be a means by which GABAA receptors get inserted into membranes;
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increased L-type current causes secretion of brain-derived neurotrophic factor (BDNF),
which has been shown to modulate GABAA expression previously (Kuczewski et al.,
2011). GABAB receptor-induced increases in L-type current also increase
phosphorylation levels of extracellular signal-regulated protein kinase 1/2 (ERK1/2, Im
and Rhim 2012). ERK1/2 is known to activate cAMP response element binding protein
(CREB, Vanhoose et al., 2002; Tu et al., 2007) as well as be involved in synaptic
plasticity (Giovannini 2006). However, while it has been shown that GABAB receptor
activation can lead to ERK1/2 activation, the targets of this activated ERK1/2 remain
unknown.
While there are few reports of GABAB receptor mediated increases in activity,
there is even less known about the signaling cascade that promotes current enhancement.
Initially, Shen and Slaughter (1999) described this enhancement as sensitive to protein
kinase C (PKC) inhibition, and somewhat less sensitive to protein kinase A (PKA)
inhibition. Furthermore, enhancement could be abolished by treatment with
dihydropyridines, verifying L-current was being affected (Shen and Slaughter 1999;
Carter and Mynlieff 2004). More recent work in our laboratory showed that, when
treated with pertussis toxin to inhibit Gαi/o protein signaling, enhancement persisted (Bray
and Mynlieff 2011). These data suggested that GABAB receptors couple to a G protein
besides the canonical Gαi/o to produce enhancement.
A large portion of my work was to determine the signaling cascade that resulted
when GABAB receptors were activated. Since Gαi/o G proteins were likely not involved,
it was hypothesized that GABAB receptors may couple promiscuously to more than one
G protein. The involvement of PKC suggested that Gαq was responsible for the observed
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current enhancement, since Gαq activation has been demonstrated to activate
phospholipase C (PLC), which increases PKC activation. In order to test this hypothesis,
I employed a strategy of morpholino (MO)-induced knockdown. Furthermore, while
PKC has been demonstrated to be a requisite member of the signal transduction pathway,
the isoform had not been identified. When cells were treated with PKC activator phorbol
12-myristate 13-acetate (PMA), a phorbol ester, enhancement of calcium current could be
reproduced (Bray and Mynlieff 2011). Because only a subset of PKC isozymes are
sensitive to phorbol stimulation, and because the enhancing effect is maximally observed
at P7, it narrowed the possible candidates to three isozymes, α, β, and ε. Finally, it was
hypothesized that calcium/calmodulin-dependent kinase II (CaMKII) was involved in this
pathway, because a report from O-Uchi et al. (2008) showed that cardiac myocytes
demonstrate enhanced L-type current as a result of Gαq signaling, also mediated by PKC
and CaMKII.
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RESULTS
Mopholino oligos effectively enter mammalian neurons grown in culture
In order to examine whether GABAB receptors exert their effects through
signaling the α subunit of the Gαq G protein complex, I employed the strategy of
knockdown via morpholino (MO) oligonucleotides. MO are synthetic oligos designed to
bind target mRNA and inhibit their translation. They are readily taken up by cells in
culture, and fused to a 3’ carboxyfluorescein molecule to visualize delivery into the cell
(figure 4.1a and b).

Figure 4.1: Introduction of morpholino (MO) oligos and their effect on cultured hippocampal
neurons. A) Differential interference contrast image of a hippocampal culture from P4 rat pups
treated with 10 µM control oligos and 2 µM Endo-Porter peptide, maintained in culture for 96
hours. B) Fluorescent image of cells pictured in A; MO were tagged with carboxyfluorescein
for visualization and assessment of delivery. C) Western blot of proteins isolated from either
control cultures (lane 1), cultures treated for 24 or 48 hours with 2 µM Gαq MO and 4 µM
Endo-Porter (lanes 2 and 3, respectively). These cultures were obtained from P6-8 rats. The
Western blot was decorated with Gαq antibodies and β-tubulin antibodies as a loading control
D) Quantification of Gαq band density. Values were calculated by dividing integrated optical
density (IOD) of the Gαq band by the IOD of the β-tubulin band to control for sample loading.
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While this strategy is common in zebrafish, there are fewer reports of their
successful use in mammalian neurons. Before proceeding with knockdown of Gαq, it was
necessary to verify that MO were able to be taken up by mammalian cells and were nontoxic. Cultures were treated with Endo-Porter, a proprietary molecule that causes
endocytosis-mediated uptake of cargo (see Chapter 2 for figure), and a nonsense MO
(one that did not bind to any known mRNA) and visualized after 24, 48, and 96 hours of
incubation. Figure 4.1 shows cultures after 96 hour treatment. Cells appear healthy,
displaying growing processes and maintaining their characteristic shape. When
examined under fluorescence, every cell displays some level of fluorescence, suggesting
universal uptake of the MO oligos. At concentrations ≥ 4 µM oligos or ≥ 6 µM EndoPorter, treatment with MO began to negatively affect growth and viability of neuronal
cultures (data not shown). Thus, 2 µM MO and 4 µM Endo-Porter were used.

Morpholino oligos effectively inhibit translation of Gαq
To determine the effectiveness of MO-induced protein knockdown, neurons were
treated with Endo-Porter alone, Endo-Porter and nonsense oligos, or Endo-Porter and
MO against Gαq G protein. Western blotting was performed either 24 or 48 hours after
treatment. Figure 4.1c shows that after 24 hours, significant knockdown was achieved.
G proteins have relatively long half-lives, up to 30 hours (Derrien et al., 1996); thus MO
were added to cell cultures for 48 hours to maximize knockdown. 48 hour treatment
almost completely abolished the Gαq protein signal. Cultures treated with Endo-Porter
alone or nonsense MO demonstrated comparable levels of Gαq protein expression as
controls (data not shown). Thus, using the Endo-Porter delivery system, Gαq protein
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expression in neuronal cultures was reduced without negatively impacting cell health or
viability, determined both physiologically (by observing characteristic intracellular
calcium increases upon depolarization) and morphologically. Due to the relatively long
half-life of G proteins, all electrophysiological and calcium imaging experiments were
performed following 48 hour incubation with Gαq to ensure the highest degree of protein
knockdown possible.

Gαq is more highly expressed than Gα11 in the neonatal hippocampus
Gα11 shares 90% sequence similarity with Gαq and both proteins have a
ubiquitous distribution pattern (Mizuno and Itoh 2009). Therefore, it was important to
determine whether there could be nonspecificity in the MO knockdown of Gαq that may
decrease expression of Gα11 as well. Protein preparations from cultured cells were
treated with either Gαq or nonsense MO and analyzed by Western blotting using Gα11
antibodies. If the MO were specific to Gαq, there would be no change in the expression
of Gα11. However, no signal was detected in these preparations, or in control
preparations not treated with MO, nor those only treated with Endo-Porter (data not
shown). This result was suggestive that either the basal level of Gα11 was too low to
detect with Western blotting in preparations of cultured neurons, or the Gα11 antibody did
not recognize its target. To determine whether the Gα11 antibody could recognize Gα11 G
protein, protein samples were prepared from the superior region of the hippocampus so
that the amount of protein loaded on a gel could be increased. Antibodies to Gαq and
Gα11 detected proteins of similar weights as expected. Figure 4.2 shows that the Gα11
antibody does recognize its target, but only if 5-10 times the amount of protein was
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Figure 4.2: Expression levels of Gαq and
Gα11 in the superior region of the
neonatal rat hippocampus. Western blot
analyses were performed on samples
using antibodies against Gαq or Gα11.
Lanes 1-4 (middle panel) were loaded
with 10 times less protein than lanes 5-7.
In order to visualize bands probed with
Gα11 antibody, exposure time was
increased to 10 minutes (right panel),
compared to 3 minute exposure used to
visualize bands probed with Gαq. The
left panel shows markers used for
molecular weight calculations.

loaded and the decorated membrane was exposed to film for a longer period of time.
When a lane loaded with 2 µg of protein was probed with Gαq antibody, the integrated
optical density (IOD) was 7.2. When a lane was loaded with 20 µg of protein and probed
with Gα11 antibody, the IOD was 5.0, on the same film with the same exposure time.
These data suggest that Gαq expression is likely 10-fold or more higher than that of Gα11.
With such a small basal level of Gα11 expressed, it is not surprising that this protein was
undetectable in Western blots loaded with cultured cell preparations. Expression data
here supports a similar previous finding that Gαq is more highly expressed than Gα11 in
hippocampal tissue.

Inhibiting Gαq expression abolishes baclofen-mediated voltage gated calcium
current enhancement
Previous studies showed that the enhancing effect of GABAB receptor activation
on L-type current was not mediated by a Gαi/o G protein, because pertussis toxin (PTX)

69
treatment eliminated only attenuation of calcium current, while enhancement persisted in
PTX-treated populations of neuronal cultures (Bray and Mynlieff 2011). Despite a lack
of precedence for GABAB receptor coupling to Gαq, downstream actions, including PKC
activation, were consistent with the actions of a Gαq G protein family member.
Therefore, we chose to knock down Gαq and assess whether application of the GABAB
receptor agonist baclofen (10 µM) could still lead to L-type current enhancement.
Hippocampal cultures treated with either nonsense or Gαq MO were stimulated with a
high KCl solution, followed by a high KCl solution containing 10 µM baclofen, and
assessed with ratiometric calcium imaging. In nonsense MO-treated cells, 6 out of 64
cells (9.37%) demonstrated enhancement of calcium entry when baclofen was coapplied
with high KCl (Figure 4.4b). This percentage is not statistically different than the
percentage of cells showing enhancement treated with only 10 µM baclofen and no
morpholinos. Conversely, none of the 207 cells treated with Gαq morpholinos
demonstrated enhancement of calcium entry when baclofen was coapplied with KCl
(Figure 4.4d, Chi square, P < 0.001). Notably, 56 of the 207 cells (27.05%) still
demonstrated inhibition of calcium entry, suggesting that Gαi/o-mediated inhibition of
channels was unaffected (data not shown). To verify the result that knockdown of Gαq
resulted in elimination of calcium current enhancement, whole-cell voltage clamp
electrophysiology was used. In control cells treated with nonsense MO, 3 out of 25 cells
demonstrated an enhancement of calcium current when baclofen was applied and cells
were depolarized to +10 mV for 300 ms (Figure 4.4a). In contrast, 0 out of 16 cells
treated with Gαq MO for 48 hours demonstrated enhancement of calcium current under
the same experimental conditions (Figure 4.4b). Though these electrophysiological
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results failed to reach statistical significance, they follow the same pattern as the highly
significant calcium imaging data. Taken together, these sets of experiments demonstrate
that knockdown of Gαq G proteins abolished enhancement of calcium current or entry
upon GABAB receptor activation, linking a Gαq family member to this pathway and thus
the GABAB receptor itself.

Figure 4.3: Effect of 48 hour treatment with Gαq MO on calcium entry in hippocampal neurons.
Neurons were treated with either nonsense MO (A and C) or Gαq MO (B and D). Voltage gated
calcium currents were elicited by a 300 ms depolarizing pulse to +10 mV from a holding
potential of -80 mV in the absence (green trace) and presence of 10 µM baclofen (red trace; A
and B). Increases in intracellular calcium were induced by high KCl solution-mediated
depolarization were measured with ratiometric calcium imaging as the ration of the intensity
when excited by 340 nm light over the intensity when excited by 380 nm light (C and D). Each
colored line in C and D represents a single cell.
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GABAB receptors colocalize with Gαq G proteins
To further examine the possibility that GABAB receptors couple to G proteins,
confocal imaging was used to determine whether these two proteins colocalize.
Hippocampi were frozen and sliced into 20 µM sections, which were decorated with
primary antibodies against GABABR1 and Gαq. When sections were labeled with
antibodies against GABAB receptors (red), nearly all areas were labeled, with the
exception of the granule cells in the dentate gyrus. Labeling was most intense in the
pyramidal cell layer and the region containing the mossy fibers; lighter labeling was also
evident in the stratum oriens and stratum radiatum. At high magnification, there was a
total absence of nuclear labeling with GABAB receptor antibodies, and a clear delineation
between the nuclei and the cytoplasm. Antibodies against Gαq labeled cells within both
the pyramidal layer and the granule cell later. In addition, there appeared to be individual
cell bodies labeled within the stratum oriens and stratum radiatum without any diffuse
labeling throughout these layers, as seen with GABAB receptor antibodies. At low
magnification, colocalization of the two fluorophores was most evident in the pyramidal
cell layer and was absent from the dentate gyrus granule cell layer. Quantitative analysis
done at high magnification in the superior region of the hippocampus supports qualitative
evidence seen at low magnification. The average Pearson’s Correlation Coefficient
(PCC), used to determine colocalization, was 0.125 ± 0.03 (S.E.M.) in the stratum oriens.
The PCC was 0.476 ± 0.03 in the pyramidal cell layer and 0.102 ± 0.01 in the stratum
radiatum. The colocalization of GABAB receptors and Gαq is highest in the pyramidal
cell layer, as suggested by the PCC value; the PCC is significantly higher in the
pyramidal cell layer than either the stratum radiatum or stratum oriens (P < 0.001). The
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Figure 4.4: GABAB receptors colocalize with Gαq G proteins in rat hippocampus. Hippocampal
sections were labeled with ployclonal rabbit anti-GNAQ and monoclonal mouse anti GABABR1
followed by Dylight® 488-conjugated goat-anti rabbit IgG (green) and Dylight® 550conjugated goat-anti mouse IgG (red) for visualization. Nuclei were stained blue with DAPI.
Colocalization of the red and green fluophores appears yellow in the merged images of (C, D,
G, H, and I) White arrowheads in (C) indicate the colocalization seen in the pyramidal cell layer
but not the dentate granule cell layer. Images in (A,B, E, and F) represent the proteins of interest
in isolation with the images merged in column 3 and nuclear staining (blue) added in column 4.
A-D: Low magnification image showing the whole section of hippocampus. E-H: High
magnification image showing the pyramidal cell layer, the stratum oriens, and the stratum
radiatum. I: A small number of cells in both the stratum oriens and the stratum radiatum
appeared to show colocalization of GABAB and Gαq with a high PCC value. One of these cells
in the radiatum is shown with a white arrowhead. J: Control sections were stained without
primary antibodies to ensure specificity. Red blood vessels can be seen due to autofluorescence.
Abbreviations: DG dentate gyrus, R stratum radiatum, P pyramidal cell later, O stratum oriens.
Scale bar = 10 µM.

radiatum and oriens are not significantly different from each other (One way ANOVA
followed by Holm Sidak pairwise comparison). It should be noted that a small number of
neurons in the stratum radiatum and stratum oriens were labeled by antibodies against
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Gαq, and some of these neurons also appeared to be labeled with GABAB receptor
antibodies. Indeed, these neurons had a relatively high (0.5 – 0.75) PCC value. The
functional significance or physiological identity of these neurons is unknown.

CaMKII activity is not involved in GABAB receptor-mediated increases in
intracellular calcium
PKC activity has been shown to be required in the signal transduction pathway
beginning with GABAB receptor activation and ultimately resulting in increased calcium
current (Bray and Mynlieff 2011). Recently, O-Uchi and colleagues described α1Aadrenoreceptor coupling to Gαq/11 to activate PKC, leading to an increase in L-type
calcium current in cardiac myocytes (2008). Importantly, this study showed that CaMKII
was a member of this pathway as well, because inhibition of CaMKII could abolish the
enhancement of L-type current. PKC has been shown to phosphorylate CaMKII, and
because L-type channels are known to be phosphorylated by CaMKII, the involvement of
CaMKII in the activated GABAB receptor pathway was investigated. Cultured neurons
were depolarized with a high KCl solution, followed by a high KCl solution containing
both 10 µM baclofen and a cell-permeable CaMKII inhibitor Ant-AIP-II (50 nM, IC50 = 4
nM). Both baclofen and Ant-AIP-II were coapplied during a 15 second pretreatment
period as well as during the high KCl application. This length of time has been
demonstrated to be sufficient for inhibition of CaMKII (Aromolaran and Blatter 2005).
22 of 255 (8.63%) of cells continued to demonstrate increased calcium entry, despite the
presence of the CaMKII inhibitor (Figure 4.5a). When the inhibitor/baclofen solution
was washed off, the response returned to original levels. Because there have been reports
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of nonspecific actions of CaMKII inhibitors on calcium channels (Gao et al., 2006; Karls
and Mynlieff 2013), the result was confirmed using a second cell permeable inhibitor,
CamKIINtide (IINtide, 250 nM, IC50 = 50 nM). A similar result was obtained where 47
of 432 (10.88%) neurons showed a reversible increase in calcium entry when baclofen
was coapplied with IINtide (Figure 4.5b). These values are not significantly different
from control cells treated with baclofen alone, where 46 of 392 (11.73%) of cells show
increased calcium entry when treated with high KCl. (Figure 4.5c, Chi square).

Figure 4.5: The increase in calcium entry due to GABAB receptor activation with baclofen is not
affected by CaMKII inhibitors. Each colored line in A and B represents a single cell. A:
Enhancement of the 340 to 380 ratio persists, despite the presence of CaMKII inhibitor Ant-AIPII (50 nM). The enhancement is reversible, shown by the washout of baclofen and Ant-AIP-II. B:
Enhancement of the 340 to 380 ratio persists, despite the presence of CaMKII inhibitor IINtide
(250 nM). The enhancement is reversible, shown by the washout of baclofen and IINtide. C:
Summary of the baclofen-mediated increase in the 340 to 380 ratio. There is no significant
difference in number of cells demonstrating this increase in controls treated with only baclofen
versus treatment with baclofen and Ant-AIP-II, or treatment with IINtide (Chi square). Total N
inset in each bar. D: Electrophysiological recording elicited by a 300 ms test pulse from a holding
potential of -80 mV to +10 mV shows persistent calcium current enhancement when baclofen and
Ant-AIP-II are present (red line) compared to a control pulse (green line).

+
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In addition to calcium imaging, electrophysiological recordings were performed
in the presence and absence of 50 nM Ant-AIP-II and 10 µM baclofen. Cells were
depolarized to +10 mV from a holding potential of -80 mV to establish a baseline
calcium current measurement. Addition of Ant-AIP-II with baclofen did not affect the
enhancement of calcium current characteristically displayed in a subset of cells in
response to baclofen alone. In these experiments, 4 of 23 (17.39%) of cells treated with
Ant-AIP-II and baclofen displayed a significant increase in calcium current (Figure 4.5d).
Thus, since neither inhibitor blocked enhancement of intracellular calcium in two
different paradigms, it is likely that CaMKII is not involved in the GABAB receptormediated enhancement of L-type current.

PKCα translocates to the membrane upon GABAB receptor activation
A previous study demonstrated that activation of PKC by phorbol esters
mimicked the effect of GABAB receptor stimulation on calcium currents in cultured
hippocampal neurons (Bray and Mynlieff 2011). Therefore, only phorbol ester sensitive
isozymes of PKC that are expressed in the early neonatal period were tested (Tanaka and
Nishizuka 1994; Roisin and Barbin 1997). Recent experiments by Mynlieff analyzed
immunohistochemical images with confocal microscopy to determine whether PKCα,
PKCβ, or PKCε translocated from the cytosol to the plasma membrane after 10 minutes
of baclofen treatment (Figure 4.6a and b). For each experiment, two different control
conditions were run in parallel with the dishes treated with baclofen. Cells were either
treated with no drugs (unstimulated) or with the phorbol ester, phorbol 12-myristate 13-
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Figure 4.6: Activation of GABAB receptors causes translocation of PKCα in cultured hippocampal
neurons. A) Prior to fixation for immunocytochemistry, cultured hippocampal neurons were treated
with control media, the phorbol ester PMA (1 μM) in media, or baclofen (10μM) in media for 10
minutes. Cultured neurons were labeled with anti-PKCα, anti-PKCβ, or anti-PKCε antibodies
followed by Dylight® 488 conjugated secondary antibodies for visualization (green). Nuclei are
stained blue with DAPI B) The percent cells demonstrating translocation of PKCα, PKCβ, and
PKCε in control cultures (black bars) was compared to the percent cells demonstrating translocation
of PKCα, PKCβ, and PKCε following stimulation with the baclofen. N=568, 478, 104, 183, 183,
and 177 for the PKCα control, PKCα with baclofen, PKCβ control, PKCβ with baclofen, PKCε
control, and PKCε with baclofen. Scale bar: 20 μm. *P < 0.0001.

acetate (PMA, 1 µM) to verify that the translocation to the membrane was visually
apparent in confocal images. Both treatment with PMA and baclofen caused
translocation of PKCα from the cytosol to the plasma membrane. A small percentage of
cells in each culture demonstrated spontaneous translocation of all 3 PKC isozymes
examined in unstimulated cultures (2.99-7.69% N = 104-568). Upon exposure to PMA
for 10 minutes, all 3 isozymes translocated to the plasma membrane in a subset of cells
(50.17% of 291 cells for PKCα, 20.34% of 188 cells for PKCβ, and 27.59% of 203 cells
for PKCε), confirming that the protocol was sufficient to demonstrate translocation
(Mynlieff, unpublished results). For PKCβ and PKCε, the percentage of cells
demonstrating translocation to the plasma membrane in the presence of 10 µM baclofen
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was not significantly different than under nonstimulating conditions. However, the
percentage of cells demonstrating translocation of PKCα with baclofen treatment (9.83%,
N = 478) was significantly higher than the percentage of cells demonstrating spontaneous
translocation under nonstimulating conditions (2.99%, N = 568; Fisher’s exact test, P <
0.0001, Mynlieff, unpublished results). Therefore, since only PKCα was translocated to
the membrane upon baclofen treatment and not PKCβ or PKCε, PKCα is most likely the
isozyme activated in the signal transduction pathway.

78
DISCUSSION

Data presented here suggest that, in contrast to the commonly described coupling
of GABAB receptors to Gαi/o G proteins, GABAB receptors can also couple to Gαq G
proteins. This polygamous coupling leads to the activation of PKCα and, independent of
CaMKII, results in enhanced L-type calcium current in neonatal rat hippocampal
cultures. The current hypothesis, shown in figure 4.7, is that once a ligand binds to the
external face of the GABAB receptor, Gαq is released from the intracellular side of the
receptor. The α subunit activates the enzyme phospholipase Cβ, (PLCβ) which cleaves
the membrane- bound phosphatidylinositol bisphosphate (PIP2) into diacylglycerol
(DAG) and inositol tris-phosphate (IP3). The conventional isozyme PKCα, which
requires both DAG and calcium for its activation, may directly phosphorylate the L-type
channel such that it passes more current when open. However, this phosphorylation
event may not be directly mediated by PKC; it is possible an unknown protein acts as an
intermediary between PKCα and the L-type channel.
In order to test the involvement of Gαq in the signal transduction pathway, I
employed a knockdown strategy which inhibits translation of target mRNA via
morpholino (MO) oligonucleotides. Traditionally, knockdown of protein expression
involves the use of siRNA; however, MO offer a number of advantages. siRNA are
sensitive to intracellular enzymes, can trigger innate immune response, and can cause
changes in the methylation state of DNA (Bayne and Allshire 2005; Judge et al., 2005;
Kawasaki et al., 2005; Marques and Williams 2005). None of these actions occur with
MO, and they have been shown to be taken up in cultured cells, through endocytosis
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stimulated by the Endo-Porter peptide (Hudziak et al., 1996). The lack of enzymatic
degradation makes MO particularly well suited for these studies because of the relatively
long half-life of G proteins. Despite these advantages, the use of MO in mammalian
systems is still relatively new compared to use in other model organisms, particularly
Danio rerio. Indeed, there is only one report of Endo-Porter mediated MO knockdown in
mammalian neurons (Chih et al., 2006). Thus, validation of protein knockdown
demonstrated here highlights the usefulness of this technique.

Figure 4.7: The current model for the pathway, which begins with GABAB receptor activation
and results in enhanced L-type current. Ligand binding to the GABAB receptor leads to the
activation of a Gαq G protein, which putatively activates PLC. The activity of PLC hydrolyses
PIP2 into DAG and IP3, which can activate PKC, specifically the α isozyme. PKCα bypasses
CaMKII, leading to changes in the L-type calcium channel, such that L-type current is enhanced
when the channel opens. Whether PKCα directly interacts with the channel is unknown.
Abbreviations: PLC phospholipase C, PIP2 phosphatidylinositol 4,5-bisphosphate, DAG
diacylglycerol, IP3 inositol trisphosphate, PKC protein kinase C.

Western blot analysis indicated that morpholinos were efficient in knocking down
Gαq in primary hippocampal cultures, but given the high similarity in G protein mRNA
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sequence to which MOs bind, it was necessary to verify specificity of this knockdown.
The most likely candidate for nonspecific knockdown was Gα11, due to its high sequence
homology with Gαq. The first 25 coding amino acids (the site of MO binding) are 92%
identical. Despite MO being designed with 100% fidelity to the target, nonspecificity
was a concern because of this sequence similarity. Furthermore, Gα11 may compensate
for missing Gαq in Gαq-deficient mice, suggesting functional overlap as well (Korhonen
et al., 2009). Data shown here suggests significantly higher expression of Gαq than Gα11,
consistent with other reports (Milligan 1993; Ihnatovych et al., 2002). However, caution
must be used in interpreting these results. Because different antibodies were used to
detect each protein, it is possible that the Gα11 antibody is less effective and simply gives
a weaker signal than the Gαq antibody, even if there is abundant protein. However, these
Western blot data agree with other reports of greater Gαq expression. Furthermore, Gαq
expression is highest during the first postnatal week (Ihnatovych et al., 2002); this
temporal peak in expression corresponds to the time when the highest percentage of
neurons demonstrate L-type calcium current enhancement with baclofen (Bray and
Mynlieff 2009).
Experimental data from both electrophysiological and calcium imaging
experiments support the hypothesis that Gαq is the G protein that couples to the GABAB
receptor, ultimately leading to enhanced L-type current. In both paradigms, knockdown
of Gαq eliminated the enhancing response. These data were supported by confocal
imaging, which demonstrated the colocalization of GABAB receptors and Gαq G proteins.
However, Mannoury la Cour et al. used an antibody/scintillation proximity assay to
demonstrate a lack of coupling between Gαq/11 and GABAB receptors (2008). One
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potential problem with this study is that the reported EC50 value for baclofen was
approximately 50 µM for Gαi/o coupling. This value is much higher than those used by
others examining Gαi/o activation by GABAB receptors. Furthermore, the enhancing
effect of baclofen on calcium current was seen at high nanomolar concentrations, while
attenuation of calcium current requires micromolar concentrations (Shen and Slaughter
1999). Thus, it is possible that the assay used by Mannoury la Cour et al. (2008) is not
sensitive enough to show Gαq/GABAB coupling at low agonist concentrations.
The functional GABAB receptor is a heterodimer consisting of two subunits,
GABAB1a and GABAB1b, of which GABAB1b interacts with the G protein. The molecular
interaction between the GABAB receptor and Gαi/o involves both the second and third
intracellular loops of GABAB1b (Havlickova et al., 2002; Duthey et al., 2002). This
interaction occurs with the extreme C-terminus of the G protein (Franek et al., 1999).
The lack of sequence homology between Gαi/o and Gαq suggests that Gαq must couple to
sites unique to those examined previously. Although this is the first example of GABAB
receptors coupling to Gαq, coupling of a receptor to multiple G proteins has been shown
previously, including receptors that couple to both Gαq and Gαi/o. Another possibility is
that the βγ subunit of the Gαi/o G protein may increase intracellular calcium by the same
pathway as Gαq. This has been shown to occur in airway smooth muscle (Mizuta et al.,
2011). In this study, stimulation of GABAB receptors activated Gαi G protein and an
increase in calcium entry was observed. When βγ subunit signaling was
pharmacologically blocked, no calcium entry was observed and IP3 production was
reduced. Furthermore, direct stimulation of PLCβ by βγ has been reported in COS-1
cells (Camps et al., 1992), and this stimulation may occur synergistically with stimulation
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by Gαq from a separately activated receptor (Smrcka and Sternweis 1993). However, if
current enhancement was mediated by Gαi/o βγ subunits, it would be sensitive to pertussis
toxin. When PTX was applied to cell cultures, baclofen-mediated current enhancement
persisted. Furthermore, since βγ signaling requires functional α subunit interaction for
proper assembly (Smrcka 2008), knockout of Gαq would likely prevent βγ from initiating
cascades as well.
One question that remains unanswered is why only a subset of neurons show Ltype enhancement when GABAB receptors are stimulated. The answer is likely that, with
16 different types of interneurons found in the hippocampus, perhaps only (a) certain
type(s) exhibit this response. Immunohistochemical data have provided clues to a more
specific, functional answer. Neurons (presumably interneurons) in both the stratum
oriens and the stratum radiatum showed colocalization of GABAB receptors and Gαq G
proteins. Studies are underway to determine which type(s) of interneuron(s) is
responsible for the current enhancement observed. By examining colocalization of Gαq
and interneuronal markers already known to colocalize with GABAB receptors, the
specific cell type that demonstrates current enhancement can be identified. For example,
cholecystokinin (CCK), somatostatin, calbindin, and neuropeptide Y all demonstrated
colocalization with GABAB receptors. These markers help define cell type. The
hypothesis is that at least one of these markers will colocalize with Gαq, which would
indicate the type of cell which exhibits L-type enhancement. Elucidating the cell type
would provide a basis for determining the physiological relevance for GABAB mediated
enhancement of L-type current.
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CHAPTER 5

Calcium/calmodulin-dependent kinase II inhibitor CK59 demonstrates nonspecific,

reversible inhibition of voltage-gated calcium channels

INTRODUCTION

Calcium-calmodulin dependent kinase II (CaMKII) is a crucial signaling
molecule involved in many of the most fundamental behaviors of neurons, such as gene
expression and synaptic plasticity due to long term potentiation. It follows that the
distribution of this protein is widespread throughout the nervous system, and makes up
between 1-2% of total proteins in neurons. Given both its importance and its abundance,
CaMKII-mediated processes are currently under intense investigation. One of the most
common ways to study the role of CaMKII is via pharmacological inhibition. Changes in
the neuron may be revealed when a specific CaMKII inhibitor is applied, allowing the
investigator to attribute these changes to CaMKII activity. Unfortunately, a common
problem with kinase inhibitors, including CaMKII inhibitors, is their lack of specificity;
they may inhibit more targets than just CaMKII. Therefore, new, more specific inhibitors
are in high demand. This demand extends to a clinical setting, where more specific
CaMKII-related drugs would help avoid potentially harmful side effects.
Over 30 different isoforms (made up of various alternatively spliced α, β, γ, and δ
subunits) of CaMKII have been reported (for review see Fink and Meyer 2002; Wayman
et al., 2011). The primary neuronal subunits are α and β, which are highly homologous.
Subunits come together either as homo- or heterododecihedromers, with each subunit
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containing a catalytic, regulatory, and oligomerization domain. The structure of CaMKII
is analogous to a flower petal, where the oligomerization domain makes up the inner
core, while that catalytic and regulatory domains form a stack of 2 hexomers (Gaertner et
al., 2004; Rosenberg et al., 2006; see figure 1.8 from introduction). When calmodulin
(CaM) binds to the regulatory domain, autoinhibition is disrupted, and the particular
subunit interacting with CaM is free to autophosphorylate neighboring subunits, which
causes their catalytic subunits to become active. CamKII inhibitors reduce the activity of
the enzyme in different ways. For example, one of the most commonly used inhibitors,
KN93, works to compete with CaM binding to the regulatory domain. This is in contrast
to an inhibitor such as autocamtide 2-related inhibitory peptide (AIP), which specifically
inhibits autophosphorylation (Ishida et al., 1995; Song et al., 2010). It follows that with
different forms of inhibition, there are many different off target effects.
CaMKII phosphorylates a wide variety of proteins to modulate their activity,
including voltage-gated calcium channels. Regulation of these channels, either positive
or negative, occurs at sites on the channel within the intracellular loops or at the N and C
termini. G protein βγ subunits (Li et al., 2004) as well as multiple kinases (Park et al.,
2006; Wang et al., 2009) have been shown to interact with all types of voltage-gated
calcium channels. Since changes in intracellular calcium concentration often work as a
switch for many physiological processes, there is a great deal of interest surrounding how
the behavior of these channels can be modified by various signaling molecules. The most
direct approach is to expose cultured neurons to cell-permeable CaMKII inhibitors and
observe what, if any, effect CaMKII inhibition has on L-type current enhancement.
However, kinase inhibitors have been complicated by nonspecificity and off target
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effects. For example, CaMKII inhibitor KN93 interacts with L-type calcium channels by
reversibly inhibiting them (Gao et al., 2006). Previously regarded as one of the cleanest,
most potent CaMKII inhibitors in existence, KN93 is not well suited to be used in my
studies, which examine calcium channel activity. Recently a compound known as CK59
was synthesized, and has been shown to inhibit CaMKII activity (Konstantopoulos et al.,
2007). While originally created to investigate the kinase responsible for insulin-mediated
GLUT 4 glucose transporter translocation, CK59 also offered an attractive option to those
studying CaMKII and calcium channels, due to its potency (IC50 < 10 μM) and cell
permeability. I selected this inhibitor because of these factors, but it was immediately
clear that similarly to KN93, CK59 displayed nonspecific inhibition in a reversible
manner. Thus, I sought to better describe this nonspecific inhibition by examining which
type of calcium channel (N-, P/Q- or L-type) was affected, as well as the potency of the
inhibition.
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RESULTS
CK59 inhibits depolarization-induced calcium entry
Ratiometric calcium imaging was used to explore the effects of CK59 and cellpermeable autocamtide-2 related inhibitory peptide (Ant-AIP-II). Ant-AIP-II is a
compound that is an analogue of autocamtide-2 related inhibitory peptide (AIP) in which
Ala3 and Val10 are replaced with Lys and Phe respectively, giving the Ant-AIP-II 10
times greater potency than AIP (IC50 for Ant-AIP-II 4 nM, versus 40 nM for AIP).
Furthermore, Ant-AIP-II contains the Antennapedia transport sequence fused to its amino
terminus to enhance cell permeability. Ant-AIP-II has been demonstrated to successfully
enter both glia and neurons (Watterson et al., 2001; Mauceri et al., 2004). Cells were
depolarized with high KCl for 30 seconds, then KCl was washed away and cells allowed
to return to baseline. Subsequently cells were pretreated with Ant-AIP-II for 15 seconds,
followed by coapplication of Ant-AIP-II and high KCl for 30 seconds. This solution was
washed away, and a final high KCl stimulation was performed. When 50 μM was CK59
applied (IC50 = 10 μM), the high KCl solution was not able to elicit as large an increase
in intracellular calcium (Figure 5.1a). However, Ant-AIP-II treatment (50 nM) shows no
significant effect of on calcium entry through voltage-gated channels using the same
experimental protocol (Figure 5.1b). This CK59-mediated effect was reversible, as the
response to the high KCl depolarization after washout was restored to baseline levels. On
average, the increase in intracellular calcium was 44.83 ± 1.88% when compared to
control levels of intracellular calcium (the increase seen when high KCl alone was
perfused onto the cells (Figure 5.1c, N = 128; paired t-test, P < 0.001). There was no
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Figure 5.1: CaMKII inhibitor CK59 but not
Ant-AIP-II signiﬁcantly attenuates the amount
of high KCl-induced increase in intracellular
calcium when measured with ratiometric
imaging. A: Example of 340/380 ratio
obtained with high KCl solution alone or high
KCl solution in the presence of 50 µM CK59.
Each line shown represents an individual cell
(N = 6). B: The same conditions as in A, but
using 50 nM Ant-AIP-II (N = 6). C: Average
change in intracellular calcium as determined
by the 340/380 ratios with KCl alone (solid
bars), KCl with CK59 (crossed hash bar, N =
128), or KCl with Ant-AIP-II (diagonal
hashed bar, N = 255, *Paired t test, P < 0.001)

significant reduction in calcium entry when neurons were exposed to Ant-AIP-II (94.68 ±
CaMKII 1.29) compared to control levels. (N = 255). Neither inhibitor had any effect on
the baseline levels of intracellular calcium. These data suggest that the novel
inhibitor CK59 shows off-target inhibition of voltage-gated calcium channels. However,
the data do not exclude the possibility that CK59 enhances the rate of calcium extrusion
in the presence of high intracellular calcium, thereby decreasing intracellular calcium
levels measured.
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CK59 decreased calcium influx in a concentration dependent manner
In order to get a measurement of the potency of the CK59-mediated inhibition of
voltage-gated calcium channels, a concentration-response curve was constructed. High
KCl-induced increases in intracellular calcium were measured in the presence of 500 nM
– 250 μM CK59. The solubility in DMSO limited the highest concentration of CK59.
Control experiments done with DMSO diluted 1:250 in Ringer’s solution with no CK59
did not affect high KCl-induced calcium influx at this concentration (data not shown).
These concentration-response curve data were fit with a 3 parameter sigmoidal curve,
which assumed that if the concentration was increased to high enough levels, all calcium
entry would be blocked. The curve generated an IC50 of 52 μM (Figure 5.2). It is
possible that this is an overestimate; if all calcium entry is not completely inhibited and
instead CK59-mediated inhibition at a concentration of 250 μM is the actual maximum,
then the IC50 would be closer to 22 μM.

Figure 5.2: Various concentrations (0.5,
5, 20, 50, 250 µM; N = 122, 51, 166, 326,
122, respectively) of CK59 were applied
to cells during high KCl-induced
depolarization. The percent inhibition of
high KCl-induced intracellular calcium by
CK59 was calculated as 100% −
(𝐹𝑢𝑟𝑎 𝑅𝑎𝑡𝑖𝑜 𝑖𝑛 𝐶𝐾59+𝐾𝐶𝑙)
(100 𝑥 (𝐹𝑢𝑟𝑎 𝑅𝑎𝑡𝑖𝑜 𝑖𝑛 𝐾𝐶𝑙) ).
Data
were fit with a 3 parameter sigmoidal
curve (r2 = 0.983), to determine an IC50
value of CK59 in decreasing calcium
influx, 52 µM.
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The effects of CK59 on voltage-gated calcium current were measured directly
using whole-cell patch clamp electrophysiology. Currents were elicited by a 300 ms
depolarizing pulse to +10 mV from a holding potential of -80 mV. CK59 was applied via
U-tube perfusion (Figure 5.3a). Calcium currents often show run-up or run-down of
current, so control currents before and after CK59 treatment were used to construct a
linear regression line surrounded by a 95% confidence interval (Figure 5.3b). If the
inhibitor had no effect, the current elicited when CK59 was present would fall within the
confidence interval. However, the total current was reduced with CK59 application, in
agreement with calcium imaging data. In all 15 cells tested, CK59 significantly reduced
the current an average of 32.05 ± 1.86% when compared to the linear regression line
(Figure 5.3a). The difference in reduction of calcium entry observed when using
ratiometric calcium imaging versus whole cell patch clamp electrophysiology likely
stems from the length of time neurons were stimulated. In calcium imaging experiments,
neurons were depolarized for 30 seconds so that the majority of calcium influx is through
long lasting L-type channels, whereas electrophysiological experiments depolarize
neurons for a relatively short 300 ms.

CK59 decreases calcium entry through more than one voltage-gated calcium
channel
Since it had previously been reported that the CaMKII inhibitor KN93 reduced Ltype calcium current, I assessed whether specifically L-type calcium channels were
similarly inhibited by CK59 with whole cell recording. Calcium currents were measured
during the final 50 ms of a 300 ms depolarizing pulse to +10 mV to minimize the
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contribution of other current components while maximizing the long lasting (L-type)
component of the current. Notably, N-, P/Q-, and R-type currents are still present during
this period, as demonstrated in figure 5.3c, where current still remains after the L-type
calcium channel antagonist nimodipine (20 μM) was used. Thus, the current remaining in
the presence of nimodipine should primarily be comprised of N-, P/Q-, and R-types of
calcium current. If CK59 only inhibited L-type channels, then the addition of CK59 in the
presence of nimodipine should not further inhibit the total calcium current because the
channels would already be blocked. Figure 5.3c illustrates the calcium current elicited in
the presence and absence of CK59 (50 μM) in a cell pretreated with nimodipine (20μM).
The current was reduced with CK59 in a reversible manner similarly to the nonnimodipine treated cells. CK59 caused a significant decrease in calcium current with an
average reduction of 27.54 ± 4.66% (N = 7, Figure 5.3c). The reduction in voltage-gated
calcium current elicited in the presence of the L-type calcium channel antagonist suggests
that CK59 may inhibit N-, P/Q-, and/or R-type current(s).
Ratiometric calcium imaging experiments were done to confirm that CK59 can
reduce calcium entry in the presence of an L-type calcium channel antagonist.
Nimodipine (20 μM) was present in the bath for the entire time course of the experiment
to block L-type calcium channels, and high KCl solution alone or high KCl solution with
CK59 (50 μM) were applied acutely (Figure 5.4). Application of CK59 under these
conditions reduced calcium entry to 43.73 ± 1.38% (N = 185) of the average calcium
entry elicited by high KCl application alone. Given that both calcium current and entry
decreased in the presence of the L-type calcium channel blocker nimodipine, it was
hypothesized that CK59 exerts its effects by inhibiting another calcium channel type than
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Figure 5.3: Calcium currents elicited by a 300 ms depolarizing pulse +10 mV from a holding
potential of -80 mV demonstrate the nonspecific effects of CK59 (50 μM) on voltage-gated
calcium channel types. A: CK59 application reduces whole cell calcium current in normal
recording solution. Currents were recorded before (black trace), during (grey trace) or after
(light grey trace) application of CK59. B: Control calcium currents were measured before and
after application of CK59 (filled circles) and fit with a linear regression line surrounded by a
95% confidence interval (dashed line). Calcium currents elicited in the presence of CK59 (grey
diamonds) fell outside the confidence interval for the control currents. The percentage of
current blocked by CK59 was calculated by comparing the current in the presence of CK59 to
the regression line for that specific timepoint. C: 20 μM nimodipine was bath applied and
voltage-gated calcium currents were recorded before (black trace) during (grey trace) and after
(light grey trace) application of CK59 (50 μM). D: 2 μM ω-conotoxin MVIIC was bath applied
and voltage-gated calcium currents were recorded before (black trace) during (grey trace) and
after (light grey trace) application of CK59 (50 μM). The traces illustrated in A, C, and D were
recorded in different neurons. E: Average decrease in voltage-gated calcium currents seen with
CK59 application (50 μM) in control bathing solution (N = 15), with 20 μM nimodipine (N =
7), and with 2 μM ω-conotoxin MVIIC (N = 5) in the bath. *Unpaired t test, P < 001.
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L-type calcium channels, suggesting a different nonspecific effect from that of CaMKII
inhibitor KN93. However, the effect of CK59 on L-type calcium channels may have
been masked because nimodipine would already be blocking L-type channels in these
experiments. Therefore, experiments were performed to address the effect of CK59 more
specifically on L-type channels.
To clarify if L-type calcium channels could also be blocked by CK59, ωconotoxin MVIIC (2 μM) was added to the bath during electrophysiological studies to
block N- and P/Q-type calcium channels. The current in figure 5.3d is drastically reduced
due to the presence of MVIIC. Comparing the raw current in 5.3c with the L-type
channel blocker nimodipine with the raw current in 5.3d with ω-conotoxin MVIIC
suggests that while L-type current is certainly present in these neurons, currents sensitive
to ω-conotoxin MVIIC (N- and P/Q-type) make up the bulk of the high voltage activated
whole-cell current in neonatal neurons of the superior hippocampus when a 300 ms
depolarizing pulse is applied. Addition of CK59 (50 μM) reduced the current even

Figure 5.4: CaMKII inhibitor CK59 attenuates the high KCl-induced increase in intracellular
calcium in the presence of L-type calcium channel blocker nimodipine, when measured using
calcium imaging. Nimodipine (20 μM) was perfused during the entire measurement period.
The 340/380 ratio was measured in response to high KCl solution before and during CK59
application (50 μM), and representative cells are shown (N = 7 shown, total N = 185). Each
line represents an individual cell.
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further, so that very little current remained when MVIIC and CK59 were simultaneously
applied. Calcium currents in these studies were decreased an average of 67.47 ± 10.38%
(N = 5; Figure 5.3d) which was a significantly larger decrease by CK59 than that seen
when ω-conotoxin MVIIC was not present (unpaired t-test, P < 0.001, Figure 5.3e).
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DISCUSSION

Data presented here show the off-target action of the CaMKII inhibitor CK59 on
voltage-gated calcium channels. Both electrically stimulated currents in whole cell
electrophysiological recording and high KCl-induced calcium influx were significantly
reduced by CK59 in a dose-dependent manner. However, determining the exact calcium
channel(s) targeted by CK59 is more difficult. Studies done in the presence of ωconotoxin MVIIC strongly argue for L-type channel inhibition. As expected, when
MVIIC was applied to the bath, the remaining current was reduced. When CK59 was
applied while MVIIC was in the bath, there was near complete extinction of current in the
majority of cells tested. However, in the presence of L-type channel blocker nimodipine,
both calcium current and calcium entry were reduced when CK59 was applied. These
data seem to contradict experiments performed in MVIIC. However, one possibility is
that when nimodipine is present, L-type current is already being blocked. Therefore, any
effect on L-type channels would be masked. The decrease in calcium levels in the
presence of nimodipine after CK59 application does suggest inhibition of additional
channels besides the L-type calcium channel. One possibility is that R-type calcium
channels are inhibited by CK59. However, R-type current in the entorhinal cortex makes
up only 11-13% of total calcium current (Castelli and Magistretti 2006). The small
amount of current seen in the cells treated with MVIIC also suggests a large component
of calcium influx is through N- and P/Q-type channels. Even if complete blockade of Rtype current was assumed, this would likely not make up for the amount of inhibition
seen in nimodipine-treated cells. There was a 27.54% reduction in whole cell calcium
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current and 56.27% reduction in high KCl-mediated calcium entry when nimodipine was
present. These data suggest that even if R-type channels are affected along with L-type
channels, there must be another channel that is inhibited by CK59.
A second possibility that is that L-type channels were not completely blocked.
This seems unlikely due to the high concentration of nimodipine used in these studies
(IC50 = 139 nM for Cav 1.2 and 3 µM for Cav 1.3, respectively; Catterall 2005). It is
more likely that at least one of the channels blocked by MVIIC is susceptible to
inhibition by CK59. In either case, it seems that CK59 inhibits L-type channels as well
as others. While the identity of the other channels that CK59 may inhibit in addition to
L-type channels is not completely clear, it is evident that CK59 has off-target effects that
inhibit the entry of calcium through voltage-gated calcium channels.
Figure 5.3d shows the effect of blocking N- and P/Q-type currents
pharmacologically with MVIIC, then applying 50 μM CK59. The result of this
experiment is that the remaining current not blocked by MVIIC is nearly completely
blocked with CK59, and this current would likely be L-type current. Figure 5.3c shows
the effect of blocking L-type current with nimodipine, then applying 50 μM CK59.
While CK59 reduces current, there is a large component that still remains. There are two
possibilities for this effect. First, it is possible that L-type channels have a lower IC50 for
CK59 than the measured 52 μM for all calcium channels collectively. Thus, a complete
block of L-type channels may occur at 50 μM. The same concentration may not
completely block N- and P/Q-current. Alternatively, it is possible that there is a
component of the current which CK59 does not inhibit whatsoever. For example, if in

96
Figure 5.3c, L-current was blocked by nimodipine and only P/Q-current was blocked by
CK59, the remaining current could be N-type current, unaffected by either inhibitor.
CK59’s IC50 for inhibition of CaMKII activity is <10 μM. Other nonspecific
CaMKII inhibitors that inhibit L-type calcium channels are more potent, both in their
primary and off-target effects. For example, the IC50 for KN93’s effect on CaMKII is
0.37 μM (Sumi et al., 1991), whereas its IC50 for L-type channel inhibition is
approximately 1μM (Gao et al, 1996). The IC50 of the structurally related inhibitor KN62
is 0.9 μM for CaMKII activity; the IC50 for its off-target effects on calcium entry is
approximately 0.5 μM (Sihra and Pearson 1995). Given the relatively close IC50 values
for primary and off-target effects of these CaMKII inhibitors, caution must be exercised
when selecting a compound to pharmacologically inhibit CaMKII activity.
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CHAPTER 6

GENERAL DISCUSSION

The central findings of work presented here detailed the signal transduction
pathway of L-type calcium current enhancement upon GABAB receptor stimulation. It
was demonstrated that GABAB receptors are capable of coupling to Gαq G proteins; this
activation leads to increased PKCα activity. As reported previously in our laboratory and
in others, this increased PKCα signal is necessary to increase L-type calcium channel
activity. The entire cascade circumvents CaMKII. However, it is not clear whether
PKCα phosphorylates L-type channels directly, or if there are more intermediaries in the
process of calcium current enhancement.

Determination of the L-type channel isoform
The neuronal L-type calcium channel has two isoforms, Cav 1.2 and Cav 1.3.
Because both channels are sensitive to dihydropyridines, there is no current way to
separate their functions pharmacologically. Furthermore, while conditional knockout
animals have been generated, there is the possibility that one isoform will be upregulated
to compensate for the loss of the other isoform. Thus, it has been difficult to ascribe
specific functions to a specific isoform. One question that remains in the signal
transduction pathway described here is which calcium channel isoform mediates current
enhancement. Expression data from the Mynlieff laboratory showed that expression of
Cav 1.2 peaks within the first week of development, then decreases rapidly. These data
have been confirmed by other investigators (Morton et al., 2013). Peak expression of Cav
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1.2 coincides with the time point where the greatest number of cells show enhanced
calcium entry after GABAB receptor activation, suggesting that Cav 1.2 is the channel
responsible for mediating this enhancement. However, Cav 1.3 is expressed at P7 as well,
albeit at lower levels. Furthermore, co-immuprecipitation and yeast two-hybrid assays
show a physical interaction between the GABAB receptor and Cav 1.3 (Park and Rhim
2010). These data suggest Cav 1.3 may be responsible for current enhancement. A final
possibility is that current enhancement occurs in both Cav 1.2 and Cav 1.3. Baclofen has
been shown to enhance calcium levels through both Cav 1.2 and Cav 1.3 when measured
in transfected HEK293 cells (Im and Rhim 2012). Thus, there is not a clear consensus
on the calcium channel isoform that mediates L-type current enhancement in cultured
hippocampal neurons.
Experiments using morpholino (MO) oligonucleotides to knock down either Cav
1.2 or Cav 1.3 will help identify the isoform mediated current enhancement. Knockdown
of Cav 1.2 would allow the effects of Cav 1.3 exclusively to be observed. For example, if
knockdown of Cav 1.2 abolishes L-type enhancement, then this is the channel targeted by
GABAB receptor activation. If enhancement persists, then Cav 1.3 must be at least
partially responsible for L-type enhancement. These studies should be feasible because
use of MO in protein knockdown have been successful in our rat cultures. However,
should MO knockdown prove unsuccessful, there is the possibility of determining which
channel mediates L-type enhancement by examining the phosphorylation state of the
channel. One drawback to this strategy is that it assumes enhancement is due to a
phosphorylation event. A second drawback is this strategy would require purification of
proteins that are not highly expressed (particularly Cav 1.3). However, identification of
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the channel remains a crucial step in elucidating the physiological relevance of L-type
enhancement.

The possibility of BDNF-mediated KCC2 expression
The influx of current through L-type calcium channels is critical throughout
development and into adulthood. During embryogenesis, L-type current is required for
neural crest cell migration and differentiation (Moran 1991). It is known that the
hippocampus is a crucial site for long-term potentiation (LTP), which underlies synaptic
plasticity. Pharmacological inhibition of L-type channels results in impaired induction of
specific forms of LTP in young (P21 - P28) rats (Kapur et al., 1998). Particularly
pertinent to studies in the Mynlieff laboratory is the relationship between the
neurotransmitter GABA and L-type current as the hippocampal circuitry matures. During
embryonic development, GABA acts as an excitatory neurotransmitter, but undergoes a
switch to mediate inhibition (for review see Blaesse et al., 2009). Depending on
experimental conditions (region of the hippocampus examined, cultured or slice
preparation, recording parameters, etc.), the switch in the effect of GABA on
hippocampal neurons ranges from P5 to P13 (Tyzio et al., 2007). This switch is based on
chloride gradients established by chloride transporters, and the transporters themselves
are regulated by calcium influx through L-type channels. Maturation of GABAergic
circuitry is dependent on GABA itself (Ganguly et al., 2001). Activation of GABAA
receptors is sufficient to open voltage-gated channels, and it is particularly the calcium
flowing through L-type channels which regulate chloride transporter expression levels
(Bray and Mynlieff 2009). Indeed, treating cultured cells with L-type channel
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antagonists reduces expression of the chloride transporter K+Cl-co-transporter 2 (KCC2,
Bray and Mynlieff 2009), the chloride transporter that is responsible for chloride efflux
during adulthood.
Currently, the precise mechanism for how changes in L-type calcium current
changes the expression of KCC2 is unknown. One hypothesis is that brain derived
neurotrophic factor (BDNF) expression upregulates the levels of KCC2 in an L-type
calcium-dependent manner. Several lines of evidence support this hypothesis. First,
BDNF levels are higher in the first two weeks of postnatal development (Sathanoori et
al., 2004), coinciding with the switch in GABAergic signaling from excitatory to
inhibitory. Secondly, GABAA-induced increases in intracellular calcium stimulate
BDNF expression. The BDNF gene is complex; it encodes 4 exons that are noncoding on
their own, as well as 4 promoters (Figure 6.1, Timmusk et al., 1993). Alternative splicing
produces a single exon which encodes the BDNF protein. Within the four exons,
transcripts that contain exon III are most sensitive to calcium-mediated induction. Within
exon III, the transcription factor CREB is required to induce expression, but it is not
sufficient. The promoter of exon III contains a binding site for 3 distinct transcription
factors, including the most distal binding site, calcium response element (CaRE1, Tao et
al., 2002). Induction of the BDNF gene can occur when CaRE1 is bound to the
transcription factor CaRF. The activity of CaRF is dependent both on neuronal type and
calcium concentration. CaRE1 does respond to depolarization when isolated from the
BDNF promoter, but exhibits cooperativity with other CaREs. Currently, there are 3
known CaREs, and transcription factors are required at each CaRE in order to express
exon III-containing BDNF. It is thought that different combinations of calcium-
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Figure 6.1: BDNF gene regions, and regulation of exon III. A: The BDNF gene can generate 8
distinct protein transcripts. There are 4 possible initial exons which can be alternatively spliced
to form a single 3’ exon. Each of the 4 splice variants may use one of two polyadenylation sites
within the 3’ untranslated region. B: The promoter III region on the BDNF gene is activated in
response to calcium influx. At least 3 transcriptional activators, CaRF (calcium response factor),
USF (upstream stimulatory factor) and CREB (calcium response element-binding protein) must
be recruited to the promoter. In addition, MeCP2 (methyl CpG binding protein 2) must also be
removed, which allows histone H3 to be acetylated (AC) and transcription of the BDNF gene to
occur. Phosphorylation of MeCP2 and CaRF occurs through calcium/calmodulin-dependent
kinases that are activated by calcium entering, in part, through L-type channels (Adapted with
permission from West et al., 98(20): 11024-11031 (2001). Copyright (2001) National Academy
of Sciences, U.S.A.

dependent transcription factors may be a mechanism for cell type specificity of gene
induction due to depolarization.
Furthermore, the methylation state of BDNF is also influenced by intracellular
calcium. Methylation of DNA commonly occurs where cytosine nucleotides reside next
to guanine nucleotides (CpGs). Methlyated CpGs bind several proteins, including
methyl-CpG binding protein 2 (MeCP2). MeCP2 binds to the promoter III region of
BDNF DNA and functions to repress expression (Zhou et al., 2006). However, an
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activity-dependent increase in calcium triggers phosphorylation of MeCP2 in a CaMKIIdependent mechanism (Chen et al., 2003). Phosphorylation of MeCP2 releases it from
the promoter and allows promoter III-dependent BDNF transcription. Thus, increased
intracellular calcium, potentially due to chloride efflux during development, can increase
BDNF activity by two distinct mechanisms.
The mechanism by which BDNF increases KCC2 expression is also complex.
Early growth response 4 (Egr4) is a transcription factor whose expression increases
during and after neuronal activity. The KCC2 gene contains a binding site for Egr4 on its
promoter (Uvarov et al., 2006). BDNF application activates TrkB receptors which lead
to increased ERK1/2 activity. ERK1/2 in turn causes increased expression of Egr4, which
is a requirement for transcription of KCC2 (Ludwig et al., 2011). Importantly, a direct
pathway between L-type calcium current and increased KCC2 has not been
demonstrated, nor has the GABAB mediated enhancement of L-type current been
implicated in changing expression of KCC2. However, it has been shown that GABAB
receptor activation increases L-type current, which results in increased levels of
phosphorylated ERK1/2 (Im and Rhim 2012). Furthermore, it has also been shown that
activation of GABAB receptors increase secretion of BDNF (Kuczewski et al., 2011).
Currently, there is not an established function for enhancement of L-type current in
response to GABAB receptor activation. However, experiments examining whether this
increased calcium changes KCC2 expression could provide a functional association that
is currently lacking.
Besides causing increased synthesis of BDNF, L-type calcium current is also
known to promote BDNF release. Spontaneous α-Amino-3-hydroxy-5-methyl-4-
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isoxazolepropionic acid (AMPA) receptor activity in CA3 induces long term potentiation
of GABAergic synaptic transmission; this potentiation is dependent on BDNF release,
which in turn is dependent on L-type calcium current (Figure 6.2, Kuczewski et al.,
2008). Spontaneous post-synaptic currents generated by AMPA receptor activity activate
L-type channels. Activation leads to a BDNF release event, where BDNF diffuses to
neighboring TrkB receptors. When these TrkB receptors are activated, a GABAA
receptor-mediated induction of long term potentiation is observed. Exactly how TrkB
receptor activation leads to an increase in postsynaptic calcium is unknown. However,
these data demonstrate that, in addition to regulating production of BDNF, L-type
calcium current may also be involved in activity-dependent release. Importantly, this
study showed that sustained glutamatergic activity is required for L-type channel
activation. Sustained glutamatergic receptor activation has been shown to downregulate
GABAB receptors through increased lysosomal degradation (Maier et al, 2010). One
hypothesis for this effect is that enhancement of L-current, perhaps through GABAB
receptor activation, is necessary to get a spike in BDNF production and release when

Figure 6.2: Influx of calcium current
through L-type channels can induce
BDNF release. The 3 step model proposes
that spontaneous AMPA receptor current
activates L-type channels (step 1). This
increased intracellular concentration
stimulates release of BDNF, which binds
to pericellular TrkB receptors (step 2).
Step 3 involves the activation of these
receptors
leading
to
long-term
potentiation that is dependent on
GABAergic signaling. Figure reproduced
with permission from John Wiley & Sons
Publishing, Inc. Kuczewski et al., 1;586
(Pt 21): 5119-5128, (2008).
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KCC2 is expressed during development. Once GABAergic circuitry has matured,
sustained glutamatergic activity supports basal BDNF levels and also downregulates
GABAB receptor-mediated L-type enhancement.

Identification of the interneuron class that displays L-type enhancement
While the pathway between GABAB receptor activation and L-type current
enhancement is now clearer, there is still a lack of understanding as to what cells are
displaying this phenomenon. Within the CA1 region of the hippocampus, there are
separate populations of excitatory pyramidal cells and inhibitory GABAergic
interneurons. Generally, the pyramidal cells are considered a single population; because
pyramidal cells make up a comparatively larger percentage of hippocampal cells than
interneurons, it is unlikely that L-type enhancement is mediated through these cells.
Conversely, there are at least 16 distinct classes of interneurons, with 12 classes that
innervate particular regions of pyramidal cells and 4 classes that innervate other
interneurons. Immunocytochemical markers, electrophysiological recording, and
morphological differences define the different classes; this classification has started to
uncover their specific functional significance. For example, one group of interneurons,
known as basket cells, provide GABAergic synapses onto the soma and proximal
dendrites of pyramidal cells (Somogyi and Klausberger 2005). Their output is localized
to control both timing and frequency of action potential generation in pyramidal cells.
Control of spike timing is required for rhythmical synchronization of pyramidal cell
networks, so basket cell output is essential in the generation of oscillatory firing.
However, although basket cells may be morphologically similar and have similar targets
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on pyramidal cells, there are distinct populations of basket cells that form 3 of the 16
classes of interneurons.
One of the 16 classes of inhibitory interneurons are basket cells that express
parvalbumin (PV) but not cholecystokinin. These PV+ basket cells show high frequency
action potential firing (150 Hz) in short duration trains (Doischer et al., 2008). Their
action potentials are locked in phase to fast oscillatory network firing, and thus provide
stable and consistent inhibitory output onto their targets. These basket cells function
differently than another class of interneurons, basket cells that express cholecystokinin
(CCK). CCK+ cells fire at more moderate frequencies (50 Hz), and their action
potentials are not timed to fast oscillations like PV+ basket cells (Lee et al., 2011). This
less dependable firing leads to asynchronous release events seen only in CCK+ but not
PV+ basket cells. Given the differences in firing frequency and precise timed firing,
these separate populations of basket cells likely make distinct contributions to the
complete neural network.
Finally, there is a third class of inhibitory interneuron that shows characteristics of
a basket cell. It is CCK+, but also exhibits immunoreactivity for vesicular glutamate
transporter 3 (VGLUT3, Somogyi et al., 2004). Because a cell that expresses a vesicular
transporter is likely functionally distinct, it is put into a separate class. However, so little
information is known about this cell type that it is possible that CCK+/VGLUT3+ cells
are actually the same CCK+ cells, but may express VGLUT3 at a particular time point.
Despite advances in methods combining imaging and physiology, how interneuronal
classes are divided is still highly debated.
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Which of the 16 inhibitory interneuron types may demonstrate L-type
enhancement? One hint comes from a study that examined colocalization between
GABAB receptors and neurochemical markers in the hippocampal CA1 region (Sloviter
et al., 1999). PV+ interneurons do not demonstrate colocalization with GABAB
receptors, which likely rules out any class that expresses parvalbumin, including PV+
basket cells. However, GABAB receptors do colocalize with interneurons expressing
CCK, somatostatin, calbindin, and neuropeptide Y. Thus, future experiments in the lab
will seek to colocalize one of these 4 interneuronal markers with Gαq, since that is the G
protein known to increase L-type current. One hypothesis is that increased intracellular
calcium drives the maturation of one or more of these interneuronal types. Although
there are 16 different interneuron classes, it is likely that not all classes mature during
development in the same way (Levitt et al., 2004). One popular mechanism for
maturation is activity-dependent regulation of gene expression. Influx of calcium,
particularly though N-methyl-ᴅ-aspartate (NMDA) or L-type calcium channels triggers a
signaling cascade that is necessary for differentiation, growth, and/or formation of
synaptic connections (West et al., 2002). It has been shown that both neuronal calcium
channel isoforms Cav 1.2 and Cav 1.3 colocalize with PV+ neurons. Furthermore,
although these interneurons express both isoforms, levels of Cav 1.3 are more widely
expressed (Jiang and Swann, 2005). This was a unique finding because it has been
demonstrated previously that approximately 80% of total L-type channels are Cav 1.2 and
only the remaining 20% are Cav 1.3 (Hell et al., 1993). This study suggested that influx
of calcium through Cav 1.3 regulated development of these PV+ interneurons via an
unknown mechanism. This is particularly interesting to our laboratory as we try to
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identify the calcium channel isoform mediating current enhancement. The idea that a
particular isoform of L-channels can regulate a particular class of interneurons is unique;
it is also intriguing to consider whether L-type current enhancement is a requirement in
neurons that depend on L-type current for maturation. It is unlikely that the cells
examined by Jiang and Swann (2005) may be those that show enhanced colocalization
with Gαq and undergo current enhancement, because GABAB receptors do not colocalize
with PV+ interneurons.

L-type current controls gene expression
The timing of L-type current enhancement is of particular interest given that this
type of current is known to regulate gene expression (Figure 6.3). The best-described
mechanism for this regulation is through activation of transcription factors. For example,
local entry of L-type current is known to activate calcineurin (Norris et al., 2002), a
protein phosphatase that dephosphorylates the transcription factor NFATc within the
cytoplasm. This dephosphorylation serves as a nuclear translocation signal, whereby
NFATc will enter the nucleus and activate gene expression (Chung and Jan 2006). Other
intermediaries, such as CaMK IV or Ras/mitogen-activated protein kinase (MAPK)
pathways also serve to transmit local rises in L-type current to global changes in gene
expression (Dolmetsch et al., 2001). Interestingly, these pathways involve the
phosphorylation of transcription factor calcium/cAMP responsive element binding
protein (CREB); activation of GABAB receptors has been shown to induce increases in
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the ratio of phosphorylated CREB to nonphosphorylated CREB, and this increase can be
blocked by treatment with L-type calcium channel antagonist nifedipine (Kuczewski et
al., 2011).
More recently, a fragment of Cav 1.2 (termed calcium channel associated
transcription factor, or CCAT) has been shown to be cleaved from the full-length protein
and act as a transcription factor (Gomez-Ospina et al., 2006). While the mechanism of
cleavage remains unclear, increasing L-type calcium current reduces the amount of
CCAT-mediated transcription that occurs. Furthermore, based on microarray data,
expression of a host of genes was shown to be both upregulated and downregulated based
on CCAT activity. One of the genes that showed the greatest increases in expression
upon CCAT recruitment to its promoter was connexin 31.1 (Cx31.1). Connexins are
proteins critical for the formation of direct electrical connections via gap junctions. The
synchronous firing pattern of interneurons is often dependent on gap junctions made up
of this connexin, and CCAT has been demonstrated to be prominently expressed in these
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cells (Connors and Long 2004). It is tempting to speculate that enhancement of L-type
current may specifically play a role in CCAT-mediated expression of Cx31.1. One
hypothesis is that as the inhibitory circuitry matures and direct electrical connections are
made, the level of Cx31.1 needs to be downregulated. By P7, when enhancement of Ltype current is greatest (Bray and Mynlieff 2011), Cx31.1 expression is inhibited, such
that exact electrical coupling between classes of interneurons is precisely controlled.
Would eliminating L-type current enhancement lead to aberrant electrical connections?
Future experiments could be designed to look at CCAT levels or Cx31.1 expression in
neurons that demonstrate L-type enhancement. If so, this would be evidence for the
specific function of Cav isoform 1.2, as neither the Cav 1.3 isoform nor the N-type
channel (Cav 2.1) C termini demonstrated any effect on transcription (Gomez-Ospina et
al., 2006).

Isozyme-specific function of PKCα in L-type current enhancement
The regulation of calcium channels by PKC has been a matter of some
controversy. The nonselective PKC activator PMA has been shown to enhance calcium
current in Aplysia bag neurons (DeRiemer et al., 1985), neuroblastomas (Osugi et al.,
1986), and frog sympathetic neurons (Yang and Tsien 1993). Paradoxically, inhibition of
calcium current has been reported in chick dorsal root ganglion cells (Rane and Dunlap
1986) and PC-12 cells (a neuroendocrine tumor cell line, Di Virgilio et al., 1986). Even
in the same cells, the effect of PKC stimulation can lead to opposite effects on calcium
current (Tseng and Boyden 1991). Thus, to define the actions of PKC requires the
identification of the isozyme of PKC that is active in a particular pathway. In cardiac Cav
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1.2 channels, phosphorylation by PKCε on the N terminus is responsible for inhibition of
L-type current (Yue et al., 2004). However, the serine at position 1928 on the Cav 1.2 C
terminus has been demonstrated to be phosphorylated by multiple PKC isoforms in
HEK293 cells, including PKCα (Yang et al., 2005). This phosphorylation led to an
increase in L-type channel activity. Conversely, stimulation with PMA decreases the
activity of Cav 1.3, mediated by PKCβII and PKCε (Baroudi et al., 2006). These results
are not inconsistent with data presented here, since enhanced L-type current in cultured
neurons is due to the actions of PKCα rather than PKCβ or PKCε. These studies also
support the hypothesis that PKC is interacting with the L-type channel directly, rather
than working through an intermediary. Furthermore, PKC is thought to associate with
the plasma membrane via binding a receptor for activated C kinase (RACK) protein,
which is generally in proximity to the target substrate (Kamp and Hell 2000). Studies
designed to examine whether L-type channels colocalize or form complexes with RACKs
would provide compelling evidence that PKCα does indeed directly phosphorylate Lchannels. This isozyme-specific regulation is also suggestive that enhancement is
occurring through Cav 1.2, and that inhibitory effects may reflect phosphorylation of Cav
1.3. It will be interesting to examine whether selective knockdown of Cav 1.3 leads to a
greater proportion of neurons demonstrating current enhancement. It is possible that the
temporal expression of Cav 1.2 and 1.3 plays a key role in governing PKC-dependent
enhancement of L-type current.
Data presented here describe a signal transduction pathway initiated by GABAB
receptor activation, resulting in enhanced L-type current in the developing mammalian

111
nervous system. Proposed experiments will help decipher what the physiological
relevance of this enhancement may be.
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APPENDIX I

The expression of interneuronal marker GAD6 in cultured hippocampal neurons

In order to examine the effects of GABAergic stimulation on calcium currents,
my studies have relied heavily on the use of P6-8 rat pups. Hippocampal cultures from
these pups have demonstrated the greatest number of neurons that demonstrate L-type
current enhancement, as opposed to either older or younger pups. Cells grown in culture
are derived specifically from the superior region of the hippocampus, primarily CA1.
Within this region, there are both inhibitory interneurons and excitatory pyramidal cells.
Inhibitory interneurons, found primarily in the stratum oriens and stratum radiatium of
the CA1 region, are more sparsely distributed relative to the excitatory neurons in the
pyramidal layer. Because tissue from the superior region of the hippocampus was known
to contain both excitatory and inhibitory neurons, a common question centers on the
makeup of these neurons in culture. This question is particularly important to work
presented here, because the GABAB mediated enhancement of L-type current is only
observed in a minority of neurons. Since excitatory pyramidal cells compose a large
percentage of total neurons in the hippocampus, it is not likely these are the neurons that
demonstrate this effect. Instead, my work has focused on GABAergic interneurons that
provide inhibitory input to the pyramidal cells. It follows that cell cultures which contain
a relatively high population of interneurons would be best to study, because more cells
would demonstrate the enhancement in which I am interested. However, in embryonic
cultures from rats aged E17-20, there are reports of cultures enriched in pyramidal
neurons (Banker and Cowan 1977). This is in contrast to reports that suggest significant
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numbers of inhibitory neurons in embryonic cultures using anti-GABA antibodies
(Mattson and Kater 1989). Understanding the makeup of the cells in culture may offer
explanations as to why only a certain subset of neurons demonstrates GABAB receptormediated enhancement of L-type current.
Studies performed in the laboratory have examined the percentage of cells in
culture that are immunoreactive for the GABA antibody, and thus assumed to be
GABAergic inhibitory interneurons (Figure A1.1). 37.5 ± 2.3% of neurons showed
GABA labeling after 24 hours in culture (Mynlieff 1997). This labeling was independent
of age; there was no significant difference in GABA labeling in neurons cultured from a
P7, P14, or P21 animal. When left in culture for longer periods, GABA labeling was
seen in more cells. Neurons cultured from a P21 animal and grown in vitro for 21 days
demonstrated that 74.2 ± 2.7% of cells were labeled with anti-GABA antibodies
(Mynlieff 1997). Furthermore, this report only gives the number of cultures examined
and not the total number of neurons labeled, so it is difficult to know how many cells
were examined.

Figure A1.1: Examples of GABA immunoreactive neurons in culture. A: Neurons from a P11
rat pup were dissociated and allowed to remain in culture 40 hours before fixation. Neurons
were labeled with mouse anti-GABA primary antibodies, and biotinylated anti-mouse IgG were
used as the secondary antibodies. Binding was visualized using a Vectastain Elite ABC Kit with
a DIC microscope outfitted with Hoffman modulation optics. B: Cultured cell control with tissue
taken from the same pup as in A. (From Mynlieff 1997)
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I sought to verify these results using antibodies against glutamic acid
decarboxylase (GAD). GAD catalyzes the conversion of glutamate to GABA and carbon
dioxide. Thus, GAD is universally expressed in GABAergic cells. Neurons that express
GABA must also express this enzyme. There are two genes which encode two isoforms
of GAD, GAD 65 and GAD 67, respectively. The antibody against GAD that was used
(GAD6) recognizes both isoforms. Using confocal microscopy, a total of 43 of 287
(14.98%) cells, isolated from 4 different animals, labeled for GAD. The total number of
cells is a sum taken from 11 different images. As expected, labeling is largely absent in
the nucleus. Furthermore, there are no gradations in labeling. It is clear which neurons
express GAD (Figure A1.2), and are therefore assumed to be GABAergic interneurons.
Notably, all neurons were isolated from P7 rat pups and kept in culture for 24 hours. The
effect of age or time in culture was not examined.

A.

B.

C.

Figure A1.2: Examples of GAD6 immunoreactive neurons in culture. Neurons from a P7 rat pup
were dissociated and allowed to remain in culture overnight before fixation. Cells were decorated
with anti-GAD6 primary antibodies and DyLight 550® secondary antibodies. A: DAPI was
applied to visualize nuclei. B: GAD6 immunolabeling was not seen in the nuclei, but was around
the periphery, often with a spot of particularly heavy labeling. GAD6 was also seen in the
processes of several neurons. C: Overlay of panels A and B.
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The immunohistochemistry performed here shows dramatically fewer neurons
than data from (Mynlieff 1997). One possibility is that the antibody used by Mynlieff
was not as specific as the GAD antibody. There are inherent difficulties in producing
antibodies to GABA. Production of an antibody to a small molecule such as GABA
requires it to be conjugated to a larger molecule; furthermore, the synthesis of GABA
from glutamic acid involves removal of a carboxyl sidegroup. These problems could lead
to production of an antibody that may recognize more than its desired target. Another
possibility is that the resolution using confocal microscopy was better suited to discern
which neurons were GABAergic. Interpreting the images seen with biotinylation,
visualized under differential interference contract (DIC) microscopy may be unclear such
that shadows or cells with a generally darker appearance may be considered positive.
Confocal imaging with GAD6 antibodies provided clear images that were easily
quantified.
Hippocampal cultures containing less than 15% inhibitory interneurons has
important implications for how data are interpreted. The current hypothesis is that since
not all neurons show GABAB receptor-mediated calcium current enhancement, there
must be a subset of inhibitory interneurons that function differentially to account for this
phenomenon. However, one possibility is that the calcium current enhancement is a
much more generalized effect. Based on the percentage of neurons that demonstrate
enhanced calcium entry when ratiometric calcium imaging is used, perhaps nearly all
inhibitory interneurons exhibit this effect. Indeed, while work in the Mynlieff laboratory
has shown calcium current enhancement to occur in only a subset of cells, other reports
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do not observe the same effect. Thus, it is possible that current enhancement is always
observed when inhibitory interneurons are selected.
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APPENDIX II

Inhibition of calcium channels by dihydropyridines as measured with ratiometric

calcium imaging

The focus of my work has been to understand the G protein coupled pathway
through which L-type calcium current is enhanced. This current enhancement was shown
to occur through L-type channels, because when L-channels were blocked with
nimodipine, enhancement was eliminated. However, the currents recorded either with
electrophysiology or the calcium entry recorded with calcium imaging, likely effects
opening of all types (L-, N-, P/Q-, R-, and T) of calcium channels. Depending on the
expression of each of these channels, whole cell calcium current may look very different
from cell to cell. Furthermore, cultured cells from CA1 are not heterogeneous, so it is
likely that there are many different cell types, and even within cell types, calcium current
profiles will vary. It is important to this work to understand the relative contribution of
L-type channels to whole cell calcium currents.
Particularly in calcium imaging, separation of current types with toxins is cost
prohibitive because there is constant perfusion occurring. Instead through a combination
of pharmacological methods and reliance on known channel kinetics, statements can be
made about the type of channel through which calcium enters. For example,
dihydopyridines nimodipine and nifedipine are selective blockers of L-type calcium
channels. L-type current derives its name because it shows little voltage dependent
inactivation (and thus is considered Long-lasting). Understanding the total makeup and
contribution of channels becomes important when trying to uncover roles for that
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particular channel. Electrophysiological recordings done in the Mynlieff laboratory by a
previous graduate student demonstrated that L-type calcium current made up less than
10% of total calcium current and was even lower in certain interneuronal classes (Figure
A2.1). For example, only about 5% of total calcium current was inhibited by L-type
channel antagonist nimodipine when applied to basket cells. However, this may be an
underestimate, since in all cases except that of vertical cells, more than 50% of current is
not blocked by N-, P/Q-, and L-channel antagonists. Initial studies measuring the
contribution to L-type current using ratiometric calcium imaging suggested entry through
L-channels was greater than that shown using electrophysiology; therefore I sought to
clarify the percentage of calcium entry flowing through L-channels using calcium
imaging and two different dihydropyridine inhibitors.

Figure A2.1: Components of whole-cell
barium current in interneurons as measured by
whole-cell patch clamp electrophysiology.
Current-clamp measurements of action
potentials were elicited by injecting a 0.1 – 0.2
ms depolarizing current of 2 – 4 nA, followed
by a switch to voltage clamp mode for
measurements of calcium currents. Barium
currents were elicited from a holding potential
of -80 mV by a 300 ms long depolarizing pulse
to +10 mV. Action potential kinetics allowed
interneurons to be categorized into classes.
Calcium channel inhibitors were used to
separate components of whole cell current.
Nimodipine was applied at 5 μM, GVIA was
applied at 3 μM. From (Carter 2002).

Several reports in the literature have attempted to describe the contribution of each type
of calcium channel to total calcium current, and each has slightly different conditions.
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For example, hippocampal cultures performed on newborn rats were grown in culture for
10-12 days. L-type current was found to be 22.7 ± 5.2% of total current (Isaeva et al.,
1998). Another study used neurons derived from E18 hippocampi. This report described
an age-dependent increase in L-type current, with the late component rising twofold from
P7 to P21 (Blalock et al., 1999). This study achieved a 40% block with nimodipine when
cells were kept in culture 21 days. A third study noted the difference in the component of
L-type current based on how long cells are kept in culture (Chameau et al., 1999). E16-18
pups were grown in culture for 4 days. When treated with nifedipine, 40% of total
current was blocked. This is in contrast to cells grown in culture for 16 days. In these
neurons, only 7% of calcium was blocked with the dihydropyridine antagonist. In
hippocampal slices of P15 – P29 rats, neurons of the entorhinal cortex showed the
greatest sensitivity to dihydropyridines, where 52-55% of current was blocked when
nifedipine was applied. Thus, it appears L-type as a proportion of total current is highly
variable depending on recording and culturing conditions.
Thus, I sought to repeat these studies and examine levels of L-channel activity
demonstrated in ratiometric calcium imaging, where the stimulation period is 3 orders of
magnitude longer (300 ms stimulation for electrophysiological recordings compared to 30
s in calcium imaging). Two structurally similar dihydropyridines, nimodipine and
nifedipine, were used to inhibit L-type channels. Neurons were first depolarized with a
high KCl solution to obtain a control value. Once it was washed away and cells returned
to baseline, the dihydopyridine was added for 15 seconds; KCl and the drug were
coapplied for 30 seconds. The response with the drug and high KCl (treatment) was
compared to the response with high KCl alone (control).

120
When nifedipine (20 μM) was applied, 33.91 ± 1.50% of the high KCl-induced
response was blocked, suggesting this was the component of total calcium entry that
entered via L-type channels (N = 278); when nimodipine (20 μM) was applied, 37.73 ±
1.39% of the response was blocked, (N = 381). These data are summarized in figure
A2.2. Furthermore, of the 659 total cells tested, only 4 showed a blockage of greater than
90%. These data suggest that when measured via ratiometric calcium imaging, L-type
current makes up a larger percentage of total calcium entry than what is observed with
electrophysiology. This percentage falls within the reported values for the contribution
of L-current in other systems.

Figure A2.2: Dihydropyridine sensitivity of cultured hippocampal neurons as measured with
ratiometric calcium imaging. High KCl was used to depolarize P7 cultured cells for 30 seconds.
KCl was perfused off, and calcium levels returned to baseline before pretreatment with either
nifedipine or nimodipine for 15 seconds. Either nimodipine or nifedipine (20 μM) plus high
KCl were coapplied for 30 s. Each bar represents the percentage of L-type current blocked
when compared with the normalized high KCl-alone response. Error bars represent SEM.
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Understanding the relative contribution of L-type entry to total entry has
important implications. Given the inherent variability of the system, questions may arise
as to whether resolving small magnitude changes are accurate. For example, if one is
measuring the ratio of calcium entry and records a baseline value of 0.30 and a peak
value of 0.90, the influx through voltage-gated channels would be 0.6. Contribution of Ltype channels would only account for approximately 30% of this change, or 0.18.
Therefore, it is possible that only cells which respond more robustly to high KCl
stimulation should be considered for analysis. This would be particularly true in studies
measuring enhancement where knockdown of either neuronal Cav 1.X isoform is
performed, and the contribution of only a single isoform is measured.
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